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The aim of the present study was to develop an alternative non-obese non-genetic rat model of 
type 2 diabetes (T2D). Six-week-old male Sprague-Dawley rats were randomly divided into six 
groups, namely: Normal Control (NC), Diabetic Control (DBC), Caffeine 5 mg/kg BW + STZ 
(CAF5), Caffeine 10 mg/kg BW + STZ (CAF10), Caffeine 20 mg/kg BW + STZ (CAF20) and 
Caffeine 40 mg/kg BW + STZ (CAF40) and were fed a commercially available rat pellet diet and 
normal drinking water ad libitum throughout the 13 weeks experimental period. After a one 
week acclimatization period, diabetes was induced in the animals in DBC and all CAF groups 
with an injection (i.p.) of the respective dosages of caffeine (mg/kg BW) 15 min before the 
injection (i.p.) of STZ (65 mg/kg BW) when normal saline was injected to the DBC group 
instead of caffeine. The NC group received normal saline and citrate buffer instead of caffeine 
and STZ, respectively. One week after the STZ injection, animals with non-fasting blood glucose 
> 300 mg/dl were considered as diabetic. Three weeks after the STZ injection, the animals in the 
CAF5 and CAF10 groups were eliminated from the study due to the severity of diabetes and the 
experiment was continued with the remainder groups for a 13 weeks period. At the end of the 
experimental period the rats were euthanized and blood and organ samples were collected for 
subsequent analysis. The data of daily food and fluid intake, weekly body weight and blood 
glucose, oral glucose tolerance test, serum insulin, fructosamine, lipid profile, organ specific and 
antioxidative enzymes, anti-diabetic drug response tests, and liver, heart, kidney and pancreas 
histopathology suggest that the CAF20 group can be a new and alternative non-obese non-
genetic chemically-induced model for T2D and can be therefore used for both chronic and acute 
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GENERAL INTRODUCTION AND LITERATURE REVIEW 
1.1 What is diabetes mellitus? 
Diabetes mellitus is a multifactorial heterogeneous metabolic disease that is characterized by, in 
addition to others, oxidative stress, hyperglycemia and dysfunctions in lipid metabolism (Islam 
and Loots, 2007). A wide spectrum of genetic and environmental factors are considered to be the 
leading causes of diabetes (Cnop et al., 2005) and some of the chronic diseases that can arise if it 
is not controlled or left untreated are diabetic neuropathy, nephropathy, retinopathy and 
cardiomyopathy (Islam and Choi, 2007).  
Diabetes is classified into two major groups namely type 1 diabetes (T1D) and type 2 diabetes 
(T2D). T1D is characterized by insulin dependence due to the severe autoimmune destruction of 
the pancreatic beta-cells which results in diminished insulin production (Islam and Choi, 2008). 
On the other hand, T2D is the most common and prevalent form of diabetes that constitutes for 
90-95% of total diabetic cases worldwide (Islam and Choi, 2009) and it is characterized by 
insulin resistance due to the progressive decline in insulin action (insulin insensitivity), followed, 
overtime, by pancreatic beta-cell dysfunction due to the inability of the pancreatic beta-cells to 
compensate for insulin resistance (DeFronzo, 1997). Some of the most common symptoms of 
T2D are polydipsia, polyphagia, polyuria and retinopathy (Lin and Sun, 2010).  
1.2 Global prevalence of diabetes mellitus 
According to the International Diabetes Federation (IDF) the estimated diabetes prevalence for 
2013 was 382 million and it is expected to reach 592 million by the year 2035 which represents 
8.3% and 10.1% of the global adult population respectively, and in 2013 alone the number of 
people died and money spent due to diabetes was 5.1 million and 548 billion United States 
Dollars (USD) respectively (IDF, 2013). According to the World Health Organisation (WHO) by 
the year 2000 the number of people with T2D worldwide and in South Africa were over 171 
million and 814 thousand respectively and by the year 2030 the projected number of diabetic 
patients with T2D is expected to reach over 366 million worldwide and 1.2 million in South 
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Africa (WHO, 2010). T2D is regarded as the fourth major cause of death in South Africa 
(Joubert et al., 2007) with a huge prevalence in Indian origin South Africans (Motala et al., 
2003). The top ten countries with the highest number of sufferers with T2D in the world are 
illustrated in Table 1.1. Majority of the countries on this list are from Asia with India and China 
occupying the top two spots closely followed by Indonesia, Japan and Pakistan. Europe 
constitutes for three countries on this list while America for two (Wild et al., 2004). Majority of 
these countries have inhabitants that are non-obese and lean and over the past decades there has 
been a huge rise in patients with non-obese T2D (Vaag and Lund, 2007). 
Table 1.1: Top ten countries in the world with the most number of type 2 diabetic patients 
in 2000 and the projected estimates for 2030 (Copied without permission from Wild et al., 
2004). 
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Some of the main reasons for this prevalence of T2D is due to oxidative stress that is associated 
with obesity, overweight, sedentary lifestyle or minimal physical activity, low fruit, vegetable 
and fibre intake, and increased intake of carbohydrates and saturated fat (Steyn et al., 2004). 
Unhealthy lifestyles have led to the high prevalence of T2D in the last 15 years in young children 
(5-12 years) and adolescents (13-19 years) (Islam and Choi, 2009), and approximately 10-20% 
of sufferers over the age of 45 years with T2D are from industrialized countries (Pietropaolo et 
al., 2007). 
As mentioned above, the key characteristic features of T2D are insulin resistance and pancreatic 
β-cell dysfunction (Defronzo, 1997) due to numerous etiological predisposing factors such as 
genetics, intrauterine environment, obesity, age, physical fitness as well as lipotoxicity and 
glucotoxicity (Vaag and Lund, 2007). Insulin resistance is defined as a state of decreased 
responsiveness to normal circulating insulin levels due to defective target tissues (Savage et al., 
2007) and as a result abnormally high insulin levels are secreted from the pancreatic beta-cells to 
control the glucose levels in the blood (Srinivasan et al., 2005). Overtime, pancreatic beta-cell 
dysfunction occurs due to lipid and glucose toxicities, defects in mitochondrial functions and 
amyloid formation (Stumvoll et al., 2005). Abnormalities in the secretion of insulin, gut incretin 
hormone and adipokines, insulin resistance of the muscles, increased hepatic glucose production, 
and alterations in adipocyte fatty acid all contribute towards the dysfunctions in glucose 
homeostasis (Vaag, 1999). From a genetic standpoint, some of the defective genes that plays a 
role in the advancement of T2D are calpain-10, insulin receptor substrate-1 (IRS-1), peroxisome 
proliferator-activated receptor γ (PPAR-γ) and glucokinase (Stumvoll et al., 2005). 
T2D is also characterized by hyperglycemia due to lowered insulin secretion, increase in 
gluconeogenesis and insulin resistance, hyperinsulinemia and hyperlipidemia (Lin and Sun, 
2010) that is commonly associated with chronic inflammation, oxidative stress and sometimes, 
hypertension and cardiovascular diseases (Ventura-Sobrevilla et al., 2011) and also shows strong 
correlations with the rising numbers of obese diabetics globally, however, in the past decade 
there has been a huge increase in incidents of T2D amongst non-obese diabetics worldwide 
specifically in Africa, Asia and Europe (Vaag and Lund, 2007). Millions of people are suffering 
from non-obese T2D in the different parts of the world particularly in Far East Asia (Nakamura 
et al., 2006), Middle Africa (Steyn et al., 2004; Olatunbosun et al., 2000) and in some European 
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countries (Alvarsson et al., 2005). Non-obese T2D is characterized by less insulin resistance and 
disorderly reduced insulin secretion, and a higher degree of total and abdominal fat masses 
(adiposity) are observed in patients with non-obese T2D despite the fact that they have a normal  
or lower body mass index (Vaag and Lund, 2007). 
Some of the leading causes of non-obese T2D may be due to the long term hyper-secretion of 
insulin in response to high calorie food intake due to westernized food habits in Far East Asian 
(Nakamura et al., 2006; Abate and Chandalia, 2007), whilst intrauterine, neonatal and childhood 
malnutrition might be the major reasons for the similar type of diabetes in many African 
countries (Steyn et al., 2004; Olatunbosun et al., 2000; Adeyi et al., 2012). 
1.3 Characteristic features of non-obese T2D 
As mentioned above, patients with non-obese T2D display disproportional reduced insulin 
secretion, less insulin resistance and a higher amount of adipose tissue in the abdominal area 
(Vaag and Lund, 2007).  
1.3.1 Insulin secretion in normal individuals and patients with T2D 
Insulin is a pleiotropic hormone that is produced in the pancreatic beta-cells which is secreted 
when the blood sugar levels are high and it regulates the blood glucose levels back to normal by 
stimulating glucose uptake in the skeletal muscle and fat cells (Wilcox, 2005). Insulin secretion 
is regulated by neural factors, nutrient contents and hormonal factors namely gastrointestinal 
hormone incretins such as glucagon-like peptide 1 (GLP-1) and the glucose-dependent 
insulinotropic polypeptide (GIP). Some of the major intracellular signals that contributes towards  
insulin secretion are ATP, Ca2+, cAMP, and phospholipid-derived inositol 1,4,5-triphosphate and 
diacylglycerol (Seino et al., 2011). 
Under normal conditions, glucose is conveyed into the pancreatic beta-cells via GLUTs 
transporters that is found on the surface of the plasma membrane. Glucose is then 
instantaneously metabolized by glycolysis and mitochondrial ATP synthesis proceeds resulting 
in an increase in intracellular ATP-to-ADP ratio. The rise in ATP/ADP ratio induces closure of 
the ATP-sensitive potassium (K+) channels, leading to the depolarization of the plasma 
membrane. In response to depolarization, L-type voltage-dependent calcium (Ca+) channels 
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begin to open resulting in an increase in intracellular accumulation of calcium that activates the 
fusion of insulin secretory granules on the plasma membrane and is commonly termed as the 
first-phase insulin release. The release of insulin from these granules occurs through a series of 
steps that are dependent on the formation of specific protein binding complexes (VAMP2, 
syntaxin 4, SNAP25) and this process is termed as insulin granule exocytosis. Soluble N-
ethylmaleimide-sensitive attachment receptor (SNARE) proteins that are located around the 
plasma membrane and insulin granules combine to give rise to a “SNAREpin” to fuse the insulin 
granules with plasma membrane, leading to a fusion pore formation through which insulin is 
released into the extracellular environment (Wiseman and Thurmond, 2012) (Figure 1.1). Studies 
have reported that polymorphisms in the transcription factor-7L2 (TCF7L2) genes and Pro12Ala 
peroxisome-proliferator-activated receptor-gamma 2 (PPARγ) genes affects the mechanism of 
insulin secretion and action in the body which is seen in patients with non-obese T2D (Vaag and 
Lund, 2007). Severe overexpression of lactate dehydrogenase-A in the pancreatic islets of 
diabetic rats that were subjected to 95% pancreatectomy had been reported to cause dysfunctions 
in mitochondrial metabolism and defects in insulin secretion (Ainscow et al., 2000). 
 
Figure 1.1: Mechanism of glucose-stimulated insulin secretion in the pancreatic β-cells 
(Copied without permission from Wiseman and Thurmond, 2012). SNAP25: Synaptosomal-
associated protein 25; VAMP2: Vesicle-associated membrane protein 2. 
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Once released, insulin binds to its specific insulin receptor and activates the receptors tyrosine 
kinase resulting in phosphorylation of insulin receptor substrates (IRS) and in the process 
activates phosphatidylinositol 3-kinase (P13K) (Kasuga, 2006). Activation of the IRS leads to 
the initiation of signal transduction (de Luca and Olefsky, 2008) while activation of P13K results 
in the stimulation of many serine kinases such as protein kinase C (PKC), phosphoinositide 
dependent kinase-1 (PDK1) and protein kinase B (Akt) that plays a crucial role in the metabolic 
functions and multifactorial actions of insulin such as suppressing gluconeogeneis, inhibiting 
GLUT4 translocation as well as influencing glucose uptake in the skeletal muscle and adipose 
tissue (Kim et al., 2008).  
The Ras-mitogen-activated protein kinase (MAPK) pathway plays a role in mediating gene 
expression and  maintains cell growth and differentiation (Kasuga, 2006). Studies have 
demonstrated that an insulin signaling pathway containing defects in PI3K, IRS, PDK1 and Akt 
dampens the metabolic actions of insulin and plays a role in the progression of T2D (Kasuga, 
2006) (Figure 1.2). Polymorphisms of the ectonucleotide pyrophosphate phosphodiesterase 1 
(ENPP1) gene have been reported to affect insulin-induced tyrosine phosphorylation resulting in 
defective insulin signaling processes in patients with non-obese T2D (Abate et al., 2005).  
 
Figure 1.2: Insulin signaling in cells (Copied without permission from Kasuga, 2006). 
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Insulin secretion occurs in a biphasic manner in order to control the blood glucose levels. The 
initial first phase of insulin release occurs quickly and lasts for a few minutes (5-10 min) and this 
is then immediately followed by a more sustained second phase of insulin secretion which occurs 
if the stimulation of glucose continues and it can last for several hours (Wang and Thurmond, 
2009). In patients with T2D, the first phase of insulin release becomes impaired which results in 
hyperglycemia, and in order to rectify this, a second phase of insulin release occurs which leads 
to a state of hyperinsulinemia. A decrease in the first phase of insulin secretion is regarded as an 
indicator of the early progression of T2D and impaired glucose tolerance (Nattrass and Bailey, 
1999) (Figure 1.3 and 1.4). 
An important parameter that plays a crucial role in monitoring the functioning of the islets is the 
pancreatic insulin reserve. In order for the pancreatic beta-cells to function sufficiently, there has 
to be a fixed pairing between insulin production and secretion (Kaiser et al., 2003). The insulin 
store size is determined by the pancreatic beta-cell mass and also by the rates of insulin secretion 
and biosynthesis. The beta-cell mass varies in adult mammals in order to adapt to insulin demand 
and it has been seen frequently during the pathological and physiological conditions of insulin 
resistance (Bernard-Kargar and Ktorza, 2001). 
Several models of glucose-stimulated insulin secretion have been developed to demonstrate the 
dynamics of insulin secretion under normal conditions and in patients with T2D (Figure 1.3 and 
1.4). There are two pools of insulin secretory granules that are found in the pancreatic beta-cells 
namely a reserve pool (RP) and readily releasable pool (RRP) which accounts for second phase 
and first phase of glucose-stimulated insulin secretion respectively (Seino et al., 2011). With 
respect to the currently existing model, under normal conditions, the RRP in the first phase are 
already docked on the cell membrane and fused upon release while in the second phase the RP 
are found further away and upon stimulation it is docked and fused to cell membrane. In 2011, 
Seino et al. reported on a newly developed model whereby, in normal conditions, in both phases 
the RRP and RP are only recruited upon stimulation which ultimately leads to fusion with 
plasma membrane. In the first phase the RRP is situated greater than 50 nm from the plasma 
membrane and it is instantaneously releasable and fused to membrane. In the second phase the 
insulin granules are secreted from the RP that is linked to the actin network via exocytosis and 
fused immediately to plasma membrane (Seino et al., 2011) (Figure 1.3).  
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Figure 1.3: Models of glucose-stimulated insulin secretion in the normal state (Copied 
without permission from Seino, 2011). RP: Reserve pool; RRP: Readily releasable pool. 
In obesity, impaired glucose tolerance (IGT) and T2D glucose-stimulated insulin secretion is 
altered in comparison to normal state of insulin secretion as explained above (Figure 4). In 
obesity, there is an increase in β-cell mass which results in high levels of insulin being secreted 
in both phases as compared to normal state. The β-cells have healthy and normal morphological 
appearance. With regards to IGT, impairment of the first phase occurs due to the reduction in 
size of the RRP as well as defective exocytotic processes while in the second phase the RP is 
reduced moderately which leads to a case of mild hyperglycemia. In patients with T2D, the first 
phase is non-existant due to the absolute loss of the RRP and the exocytotic pathway becomes 
defective. A decrease in the RP and disruptions from the actin networks results in a reduced 
functioning second phase hence leading to a state of chronic hyperglycemia (Seino et al., 2011) 
(Figure 1.4).  
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Figure 1.4: Dynamics of insulin secretion in individuals with obesity, impaired glucose 
tolerance and T2D (Copied without permission from Seino, 2011). Line (a) highlights the 
secretion of insulin in the disease state and line (b) shows the secretion of insulin in the normal 
state and. RP: Reserve pool; RRP: Readily releasable pool; IGT: Impaired glucose tolerance. 
Due to the above mentioned abnormalities in insulin secretion, patients with impaired glucose 
tolerance and acute T2D have a fasting blood glucose levels of 120-140 mg/dl or 6.7-7.8 mmol/L 
and over 140 mg/dl or  greather than 7.8 mmol/L respectively. Fasting blood glucose levels for 
non-diabetics are usually lower than 100 mg/dl or less than 5.5 mmol/L (Defronzo, 1992). 
1.3.2 Insulin resistance 
Insulin resistance occurs when the liver, adipose tissue and skeletal muscle are unable to respond 
to insulin properly (Hirabara et al., 2012) and plays a crucial role in the development of T2D due 
to defective fatty acid metabolism and it is regarded as a great predictor for determining whether 
or not a person is at risk of developing diabetes (Shulman, 2000). Pro-inflammatory cytokines 








skeletal muscle, adipose tissue and liver (de Luca and Olefsky, 2008). Lipid-induced 
mitochondrial dysfunctions have also been reported to play a critical role in insulin resistance by 
causing an impairment in insulin signaling due to the excessive production of reactive oxygen 
species (Kim et al., 2008). Non-obese patients with T2D have less insulin resistance since they 
have a much lower degree of adipose fatty tissue as compared to obese patients (Vaag and Lund, 
2007). 
The skeletal muscle is the main site for glucose disposal and accounts for about 75% of total 
insulin-stimulated glucose uptake in the human body (DeFronzo and Tripathy, 2009), and due to 
insulin resistance reduced glycogen synthesis and glucose transport occurs which results in little 
to no clearance of glucose in the blood (Gray and Kim, 2011). Due to the presence of insulin 
resistance in the liver, an over production of glucose occurs due to an enhancement in  
gluconeogenesis and glycogen breakdown that leads to a state of fasting hyperglycemia which is 
considered to be a key feature of T2D. With regards to the adipose tissue, insulin resistance 
causes an abnormally high increase in lipolysis by causing excess breakdown of triglycerides to 
fatty acids thus leading to increased serum free fatty acid levels (Gray and Kim, 2011). 
The proposed mechanism of fatty acid-mediated insulin resistance is highlighted in Figure 1.5. 
Excessive fatty acids that are released from the insulin resistant adipose tissues promotes a high 
lipid uptake and accumulation of ceramide, diacylglycerol and fatty acyl CoAs which activates 
the serine kinases such as S6-kinase, IκB kinase-β (IKK-β), protein kinase C (PKC)-θ and c-Jun 
NH2-terminal kinase (JNK) that plays a role in serine phosphorylation (Ser-P) of the insulin 
receptor substrate (IRS). This causes a reduction in both insulin-mediated tyrosine 
phosphorylation (Tyr-P) of IRS as well as insulin signaling proteins such as phosphoinositide-
dependent kinase (PDK), phosphatidyl-inositol-3 kinase (P13K) and Akt (Gray and Kim, 2011) 
which leads to increased glucose production, decreased glucose uptake and reduced insulin 
secretion (Kim et al., 2008). Inflammation of the adipose tissue also plays a role in insulin 
resistance. Inflammatory cytokines namely tumor necrosis factor (TNF)-α and interleukin-6 (IL-
6) which are secreted from the macrophages and adipocytes binds to their particular receptors, 
IL-6R and TNFR, on the cell surface that leads to the activation of signal transducer and 
activator of transcription 3 (STAT3). This increases the expression of suppressor of cytokine 
signaling (SOCS)-3 that causes ubiquitine-mediated degradation of the IRS proteins. The 
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cytokines tend to also activate JNK which causes a serine phosphorylation of IRS proteins thus 
leading to insulin resistance (Gray and Kim, 2011) (Figure 1.5). 
 
Figure 1.5: Proposed mechanism of fatty acid-mediated insulin resistance (Copied without 
permission from Gray and Kim, 2011).  
The mechanism of fatty acid induced insulin resistance in the muscle and liver are presented in 
Figure 6. Due to decreased mitochondrial oxidation and increased fatty acid delivery, fatty acid 
metabolites namely long chain acylcoenzymeA (LCCoA) and diacylglycerol (DAG) accumulate 
inside the myotubules of the muscles and the hepatocytes of the liver which results in the 
activation of  the serine/threonine kinase cascade involving novel protein kinase Cs (nPKCs), 
IκB kinase-β (IKKβ) and Jun kinase-1 (JNK-1). This leads to the serine/threonine 
phosphorylation of insulin receptor substrate (IRS) sites, thus inhibiting tyrosine phosphorylation 
of IRS-1 (muscle) and IRS-1/2 (liver) as well as phosphoinositol 3-kinase (P13-kinase). As a 
result, in the muscle, reduced insulin-stimulated glucose transport occurs and in the liver, there is 
an increase in gluconeogenesis and a decrease in glycogen synthesis thereby leading to insulin 
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resistance (Savage et al., 2007) (Figure 1.6). In the muscle, glucose transporter 4 (GLUT4) 
translocation to the cell surface is prevented resulting in no glucose entry into the cells 
(DeFronzo and Tripathy, 2009). This results in a substantial increase in blood glucose levels 
leading to a state of hyperglycemia due to diminished insulin signaling (Shulman, 2000). 
 
Figure 1.6: Proposed mechanism of fatty acid-mediated insulin resistance in the muscle and 





1.3.3 Adipose tissue and its role in insulin resistance 
The adipose tissue is one of the biggest heterogeneous endocrine organ that accounts for 
approximately 10-20% of total glucose utilization in the human body and it is composed of a 
network of nerves, vascular cells, macrophages, adipocytes, pre-adipocytes and fibroblast cells 
that can lead to a wide variety of metabolic abnormalities (Iozzo, 2009). Some of the fat-derived 
products of the adipose tissue and its role in modulating insulin sensitivity and causing insulin 
resistance is summarized in Figure 1.7 (Iozzo, 2009). Leptin, IL-6 and TNF-α are considered to 
be associated with the ongoing process of pancreatic β-cell destruction that is seen in T2D 
(Donath et al., 2003). Unaltered levels of tumour necrosis factor α (TNF-α) are found in patients 
with non-obese T2D, however, they tend to have elevated plasma levels of interleukin-6 (IL-
6)and free fatty acids (Hansen et al., 2010) and lower plasma levels of leptin, adiponectin and 
resistin (Iozzo, 2009). 
 
Figure 1.7: Adipose-derived products and its role in insulin resistance and metabolic risk 





Non-obese individuals with T2D display signs of increased abdominal obesity, expandable total 
fat masses and less adipose tissue from the waist down, however, they tend to have a normal 
body mass index (Rasmussen et al., 2005; Yajnik et al., 2002; Vaag and Lund, 2007). 
Expandable adipose tissues are less inflammed and therefore have the ability to accumulate more 
lipids resulting in less ectopic fat deposits in non-adipose tissues (Rasouli and Kern, 2008). 
Ectopic fat is characterized by triglyceride deposits in non-adipose tissues cells such as the liver 
and muscle, and it is considered to be a vital biomarker for assessing metabolic activities and the 
role it plays towards insulin sensitivity. Obesity is associated with high ectopic fat accumulation 
due to inflamed adipose tissues as compared to non-obese individuals (Lettner and Roden, 2008). 
During obesity, insulin resistance is high which causes excessive breakdown of triglycerides into 
fatty acids in the adipose tissue leading to a state of hyperlipidemia, however, in the case of  non-
obese and lean individuals they tend to have less insulin resistance and relatively lower rates of 
lipolysis occurring (Gray and Kim, 2011; Vaag and Lund, 2007). Expandable fat tissues of non-
obese individuals have low levels of free fatty acids, TNF-α, and IL-6, and high levels of 
adiponectin, conversely, during obesity the fat tissues are inflamed and the opposite occurs 
which can primarily explain for the differences in insulin resistance amongst these groups 
(Lettner and Roden, 2008).  
Due to changes in hormonal and nutritional factors in the uterus, babies that are born with a low 
birth weight have more fat and are at a high risk of developing cardiovascular and metabolic 
diseases in adulthood (Fernandez-Twinn and Ozanne, 2006). In 2002, Yajnik et al. reported that 
babies with low birth weights are exposed to higher adiposity and insulin resistance syndrome 
during childhood which correlates with the relative hyperinsulinemia and adiposity that 
originated at birth (Yajnik et al., 2002). Weight loss can reverse insulin resistance of the muscle 
and liver, however, insulin resistance of the adipose tissue cannot be reversed (Viljanen et al., 
2009) and this is further validated by studies reporting that defects in GLUT4 translocation are 
reversible and inducible in the myocytes but not in the adipocytes (Cahovà et al., 2007). 
Taking into account all the above mentioned characteristic features of non-obese T2D and its 
prevalence worldwide, more studies have to be conducted in order to fully understand the 
underlying mechanisms behind the pathogenesis of this metabolic disease. For decades scientists 
have been attempting to develop animal models of non-obese T2D as a solution to better 
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understand the pathophysiology behind this disease and to perform pharmacological screening of 
drugs to curb this heterogeneous disease.  
1.4 Overview of currently available non-obese animal models of T2D 
Animal models of T2D are used to investigate the metabolic, morphological, genetic and 
endocrine changes as well as aetiopathogenic mechanisms that lead to the development of T2D 
in humans (Srinivasan and Ramarao, 2007). Almost 85% of all animal models are developed 
using rats (US Department of Agriculture, 1989) due to their short generation time (Chen and 
Wang, 2005), smaller size, tranquil behavior, ease of handling, omnivorous nature and low 
maintenance costs (Islam and Loots, 2009; Wilson and Islam, 2012). In addition, these models 
have been used to test medicinal compounds and plant extracts for anti-diabetic potential which 
have proved to be fruitful, however, all the currently available models possess limitations in their 
use. To date, two major types of models are present for T2D research, namely genetic models 
(spontaneously induced models) and non-genetic models (experimentally induced non-
spontaneous models) and they are further classified as being an obese or non-obese model 
(Masiello et al., 1998). 
1.4.1 Genetic models of non-obese T2D 
Genetic models displaying features of non-obese T2D have been widely used to date. The Cohen 
diabetic rats (Weksler-Zangen et al., 2001), Spontaneously Diabetic Torii (SDT) rats (Shinohara 
et al., 2000), Goto-Kakizaki rats (Kitahara et al., 2002), eSS rats (Daniele et al., 2010), Akita 
mouse (Schmidt et al., 2011) and recently developed JYD mice (Oh et al., 2008) have been 
reported as the genetic models of non-obese T2D. In 2008, Oh et al. developed a non-obese JYD 
mice model by mating male DBA/2 mice with female C57BL6/J mice to study the role of 
caveolin from the skeletal muscle in the development of age-related non-obese T2D. This model 
showed hyperglycemia, insulin resistance and hyperinsulinemia without the presence of obesity 
and it was concluded that this model plays a vital role in studying ageing-dependent non-obese 
T2D and it was found that the induction of caveolin production is vital to delay the development 
of T2D (Oh et al., 2008).  
Goto-kakizaki rats are used to study the diabetes related complications such as neuropathy, 
retinopathy and peripheral nerves lesions. The limitations to this model is that beta-cell 
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destruction occurs very early, conversely, in T2D there is a progressive destruction in β-cells 
after a considerably period of time. The Akita mouse is characterized by hyperglycemia, 
polyuria, polydipsia and hypoinsulinemia due to the gradual loss in β-cell mass (Chatzigeorgiou 
et al., 2009). 
The advantages of these models is that they exhibit features of human T2D namely reduced 
pancreatic beta-cell mass and insulin resistance (Islam and Loots, 2009), however, they do 
possess many disadvantages namely highly sophisticated maintenance, they are very expensive 
to develop and are not widely available (Srinivasan and Ramarao, 2007; Nakamura et al., 2006) 
and many of them do not show closely accurate correlations to human clinical conditions 
(Masiello et al., 1998). 
Numerous transgenic/knock-out non-obese genetic models have been developed over the last 
few decades for investigating the roles that genes play on peripheral insulin action (Masiello et 
al., 2006). The glucokinase or GLUT2 gene knockout mice, human islet amyloid polypeptide 
overexpressed rat (HIP rat), PPAR-γ tissue specific knockout mouse and IRS-1/IRS-2 knockout 
mice are examples of the currently available models and they are made diabetic by deleting and 
disrupting vital genes that plays a role in preventing diabetes (Srinivasan and Ramarao, 2007). 
For example, animals with deleted or disrupted IRS-1/IRS-2 genes tend to develop sever insulin 
resistance due to defects in insulin secretion and action (Withers et al., 1998). 
The maternally expressed 1/ growth factor receptor-binding protein 10 (Meg1/Grb10) genes 
over-expressed mice has been developed recently (Meg1 Tg mice model). This model displayed 
signs of hyperinsulinemia and when given high fat diet, the rate of diabetes development 
increased by 60% thus resembling human T2D. Plasma insulin, resistin, adiponectin and 
triglyceride levels were significantly higher in this model, and the body and liver weights as well 
as the visceral fat weight was significantly lowered thus resembling features of non-obese T2D 
(Yamamoto et al., 2008). The functions of genes and mutations towards diabetes progression can 
be investigated in these models, conversely, they are extremely expensive and requires vast 




1.4.2 Experimentally induced rodent models of non-obese T2D 
As compared to genetic models, these models are very user friendly and cost effective to develop 
and maintain especially in developing countries. Rodents are advantageous in developing models 
of T2D because of their tranquil behavior, easy to handle, smaller size and low housing costs 
(Wilson and Islam, 2012). Animal models of T2D that are experimentally induced can be 
developed by dietary manipulation and by chemical means or a combination of both. These 
models exhibit features of insulin resistance and partial pancreatic beta-cell dysfunctions, 
however, none of these models to date shows all the symptoms and pathogenesis of human T2D 
(Islam and Loots, 2009; Srinivasan and Ramarao, 2007). 
1.4.3 Diet induced rodent models of non-obese T2D 
In 2012, Adeyi et al. reported on a newly developed food-induced non-obese T2D rat model. 
Male Wistar rats (150-180 g) were subdivided into three groups namely control group, alloxan-
induced insulin dependent diabetes mellitus (IDDM) (T1D) group and food-induced non-insulin 
dependent diabetes mellitus (NIDDM) (T2D) group. The control group were given a standard rat 
pellet diet and water only while the alloxan-induced group were administered with 150 mg/kg 
body weight alloxan monohydrate. The food-induced group were given white bread with a high 
glycemic index of 70 for 8 weeks and granulated sugar with a glycemic index of more than 100 
that was dissolved in water at a concentration of 1 g/ml. Rats with fasting blood glucose levels 
more than 200 mg/dl were considered as being diabetic. Glycosuria was present in both groups 
and the mean blood glucose levels for the alloxan- and food-induced groups at the end of the 
experimental period was 378.5 ± 3.9 and 270.2 ± 2.7 mg/dl respectively. The food–induced 
group had a significantly lower concentration of urea, protein, calcium and potassium and 
significantly higher hematological indices compared to the alloxan-induced group. The alloxan-
induced group had lower coronary risk indices and significantly increased antioxidant enzymes 
activity compared to the food-induced group. Histopathological examinations of the pancreas 
revealed a huge degeneration of the pancreatic islets in alloxan-induced group which was more 
of T1D while the food-induced group and control group had no visible lesion. Both diabetic 
groups had high degeneration of the glomeruli and hepatocytes in their kidney and liver 
respectively. It was concluded that foods with low fat index and high glycemic index can be used 
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to develop T2D animal models and it displayed signs of hepatopathy, nephropathy, 
hyperlipidemia, acute anemia and ionoregulatory disruptions that are seen in patients with non-
obese T2D (Adeyi et al., 2012). As seen with other models developed, this model shows many 
flaws in its execution and design. It has not been validated by the anti-diabetic drug response 
tests, hence making it not a suitable model for testing medicinal compounds and herbal infusions. 
In addition, the food-induced group was fed the above mentioned high glycemic index diets for 8 
weeks, however, for the alloxan-induced group, diabetes was only induced on week 6 of the 8 
weeks experimental period. This is a major flaw when comparing the data obtained for the 
different biochemical parameters for these two groups which can give inaccurate results. 
1.4.4 Chemically induced rodent models of non-obese T2D 
 Adult alloxan/ streptozotocin induced rodent models 
Alloxan is a derivative of uric acid and selectively destroy the pancreatic beta-cells by a necrotic 
oxidative stress mechanism. Alloxan-induced models develop chronic hyperglycemia, 
hyperlipidemia, glucosuria, polydipsia and polyphagia and show features more of T1D (Lenzen, 
2008). Streptozotocin (STZ) (2-deoxy-2-(3-methyl-3-nitrosourea)-1-D-glucopyranose), on the 
other hand, is a naturally occurring antibiotic derived from the soil bacterium Streptomyces 
achromogenes (Ventura-Sobrevilla et al., 2011; Rees and Alcolado, 2005) and it is a structural 
analogue and nitrosourea derivative of N-acetylglucosamine (GlcNAc) (Konrad et al., 2001) 
(Figure 1.8). Rakieten et al. (1963) discovered the diabetogenic properties of STZ in rats and 
dogs in the form of hyperglycemia by causing pancreatic beta-cell destruction (Srinivasan and 
Ramarao, 2007).  
STZ inhibits DNA synthesis in mammalian cells by generating free radicals which damages the 
chromosomes and DNA (Bolzan and Bianchi, 2002). STZ impedes the glycoside hydrolase O-
GlcNAc-selective-N-acetyl-β-D-glucosaminidase (O-GlcNAcase) activity in the beta-cells which 
is accountable for eliminating O-GlcNA from proteins. As a result, irreversible O-glycosylation 
of intracellular proteins occurs which leads to beta-cell apoptosis (Ventura-Sobrevilla et al., 
2011). It selectively destroys the pancreatic beta-cells by inducing necrosis and the glucose 
moiety of STZ enables it to enter the beta-cells through GLUT2 receptors (Elsner et al., 2007). It 
is postulated that STZ causes a high increase in reactive oxygen species (ROS) which causes 
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subsequent DNA damage and this leads to the activation of DNA repair enzyme poly (ADP-
ribose) polymerase-1 (PARP-1) that utilizes intracellular nicotinamide adenine dinucleotide 
(NAD). As a result NAD is depleted followed by the depletion of ATP and this ultimately leads 
to the destruction of the pancreatic β-cells (Szkudelski, 2001). Some of the STZ-generated ROS 
that plays a role in cytotoxicity and DNA damage are nitric oxide, hydroxyl radical, hydrogen 
peroxide and superoxide (Bolzan and Bianchi, 2002). 
 
Figure 1.8: Chemical structures of (a) glucose (b) N-acetyl glucosamine and (c) 
streptozotocin (Copied without permission from Ventura-Sobrevilla et al., 2011). 
Studies have found that rats develop hyperglycemia within 72 hours after administration of a 
single dose of STZ by intraperitoneal or intravenous injections at concentrations of 40 mg/kg, 50 
mg/kg, 55 mg/kg, 60 mg/kg and 65 mg/kg (Casey et al., 2004; Gojo et al., 2007; Shah and 
Singh, 2006; Singh et al., 2006; Al-Qattan et al., 2008). The loss of pancreatic beta-cells after 
STZ administration is estimated to be 80 %, however, due to the beta-cell regenerative 
mechanisms they tend to increase to approximately 50 % (Masiello, 2006). The administration of 
a single high dose of STZ (higher than 60 mg/ kg body weight) in animals causes a huge loss in 
beta-cells and they tend to be more of T1D, conversely, a low dose (40-45 mg/kg body weight) is 
more adequate to develop models of T2D (Srinivasan et al., 2005). 
 
 
(a) (c) (b) 
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 Neonatal alloxan/ streptozotocin induced rodent models 
 
Neonatal models are developed using STZ or alloxan and have been developed since 1970’s 
(Portha et al., 1989). To develop STZ or alloxan induced neonatal models, STZ or alloxan is 
injected to rats immediately after birth or neonatally and over time they develop T2D during 
adulthood. A single STZ injection at 80-100 mg/kg body weight can be given to neonatal Wistar 
rats to develop diabetic conditions closely resembling T2D as they progress to adulthood 
(Bonner-Weir et al., 1981). By week 4 they are moderately hyperglycemic (Giddings et al., 
1985). After 6-8 weeks of STZ injection at a concentration of 90-100 mg/kg body weight, Wistar 
rats develop non-fasting chronic hyperglycemia. Rats that were injected at birth and at 2 days of 
age have plasma glucose concentration of 170-200 mg/dl and 200-350 mg/dl respectively and 
they display impairments in glucose tolerance and insulin responsiveness (Masiello, 2006). The 
administration of a single dose of alloxan at a concentration of 200 mg/kg body weight to male 
neonatal rats at age 2, 4 or 6 days have been reported to induce T2D (Kodama et al., 1993). 
These models are useful for studying the regenerative mechanisms of beta-cells and to monitor 
early defects in insulin action (Srinivasan and Ramarao, 2007). They also display features of 
glucose intolerance and hyperglycemia, however, they have not yet been validated by anti-
diabetic drugs thus making them restricted in their use (Islam and Loots, 2009). 
 
 Streptozotocin-nicotinamide induced models 
 
Nicotinamide has been reported to protect the pancreatic β-cells against toxic compounds such as 
STZ (Hoorens and Pipeleers, 1999). It is a direct precursor of nicotinamide adenine dinucleotide 
(NAD) and an inhibitor of the enzyme poly (ADP-ribose) synthetase which is activated by STZ-
induced DNA injury. Due to its inhibitory effects on this enzyme, the apoptosis of pancreatic β-
cells are reduced thus increasing its survival rate (Masiello et al., 1998). 
 
In 1998, Masiello et al. originally developed the STZ-nicotinamide (STZ-NA) model using 3 
month old male Wistar rats. Nicotinamide at dosages of 100, 180, 230 and 350 mg/kg body 
weight was administered to the rats 15 minutes before STZ injection. Animals that were given 
230 mg/kg body weight nicotinamide displayed non-fasting hyperglycemia (155 ± 3 mg/dl) that 
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was stable and moderate throughout the experimental period, and had 40% preservation of 
pancreatic insulin stores. It was concluded that 230 mg/kg body weight nicotinamide was the 
ideal dosage for developing this model and it was further validated by the anti-diabetic drug 
response test (Masiello et al., 1998). Nakamura et al. (2006) further modified this model and 
developed a non-obese model of T2D using C57BL/6J mice. At days 0 and 2 of the experimental 
period, the mice were injected with 240 mg/kg body weight nicotinamide 15 minutes before the 
administration of STZ at a concentration of 100 mg/kg body weight, and they were also fed on a 
high-fat diet that closely resembles the high calorie westernized diets that non-obese patients 
with T2D are consuming in Asian countries. This model had significantly elevated levels of 
HDL-cholesterol, triglycerides and total cholesterol. The pancreatic insulin content was retained 
by 43% and the pancreatic tissues had less damage compared to the diabetic control group. High-
fat diet caused hyperlipidemia and significantly increased insulin resistance in this model. This 
model has also been validated by anti-diabetic drugs (Nakamura et al., 2006).  
 
This model is advantageous since it can be developed within 5 weeks and it resembles the 
pathophysiological characteristics of non-obese Asian patients with T2D namely inadequate 
insulin secretion as opposed to insulin resistance. It is also characterized by mild glucose 
intolerance, altered fasting blood glucose levels, as well as normal weight gain and insulin 
secretion (Nakamura et al., 2006). 
 
1.4.5 Surgical rodent models of non-obese T2D 
 
 Partial pancreatectomized models 
 
Partial pancreatectomized rat models that had 85-90% of their pancreas removed display 
moderate hyperglycemia for 6 weeks with no significant differences in body weight and serum 
insulin. After 7 weeks they displayed normal insulin concentrations and fasting blood glucose, 
however, they became postprandially hyperglycemic after an intraperitoneal glucose tolerance 
test (Bonner-Weir et al., 1989). In 2000, Kurup and Bhonde reported the development of a more 
stable model of T2D that was produced in BALB/c mice which had 50% of their pancreas 
removed and they were then treated with nicotinamide and STZ at dosages of 350 mg/kg body 
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weight and 200 mg/kg body weight respectively. This model displayed reduced serum insulin 
levels, significantly higher fasting blood glucose levels and a dramatic loss in body weight which 
is mostly associated with insulin dependent diabetes mellitus (Kurup and Bhonde, 2000). These 
models are advantageous since they do not require cytotoxic chemicals to develop and they have 
reduced beta-cell mass as seen in human T2D. However, this model require sophisticated 
technical expertise to develop, digestive problem occurs due to the excision of the endocrine 
portion of the pancreas which leads to a deficiency in amylase enzyme and have high mortality 
rates (Srinivasan and Ramarao, 2007). 
 
 Intrauterine growth retardation models  
 
Intrauterine growth retardation (IUGR) occurs due to malnutrition, genetics, multiple births and 
chronic maternal disease and as a result infants are born with a low birth weight (Ergaz et al., 
2005). Malnutrition of the fetus results in alterations in gene expression as well as functionality 
of cells in the muscle, liver and pancreas (Reusens et al., 2011). In 2008, Park et al. reported that 
the gradual epigenetic silencing of pancreatic and duodenal homeobox 1 transcription factor 
(Pdx1) occurs in the fetus when insufficient nutrients are available and this gradual reduction in 
Pdx1 occurs until adulthood thus leading towards the onset of T2D. Pdx1 plays a crucial role in 
the development of the pancreas and beta-cell differentiation. A significant decrease in Pdx1 
expression is associated with the development of T2D, beta-cell dysfunctions and insulin 
resistance occurs. In the IUGR model, 50% of the Pdx1 mRNA levels are reduced, at birth the 
beta-cell mass appears normal buts its mRNA levels are decreased and in adulthood the beta-cell 
mass is reduced and the Pdx1 expression is absent (Park et al., 2008). 
An IUGR model was developed through bilateral uterine artery ligation at 19 days of gestational 
period by restricting the blood flow to the fetus which results in limited availability of nutrients. 
The neonatal rats had low birth weight until 7 weeks of age and by week 26 they became obese 
and displayed a higher degree of adipose tissues. From a very early age the IUGR rats showed 
features of insulin resistance and glucose intolerance, and by week 7 they had mild fasting 
hyperinsulinemia and hyperglycemia, however, by week 26 they were significantly 
hyperglycemic with a fasting blood glucose level greater than 200 mg/dl which is the indication 
of T2D (Simmons et al., 2001). 
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This model is advantages since it closely resembles the progression of T2D in humans namely 
insulin resistance at a very early age followed by the development of hyperglycemia which 
overtime causes dysfunctions in the pancreatic beta-cells. Limitations are that it takes more than 
3 months for the development of T2D and requires and developing these models require good 
technical skills and accuracy (Simmons et al., 2001).  
1.5 Anti-diabetic drugs that are used to validate animal models of T2D 
 
In order to validate the newly developed animal models, anti-diabetic drug response tests are 
done to assess its suitability in testing drugs and medicinal compounds for anti-diabetic 
activities. Anti-diabetic drugs that are classed as insulin sensitizers (metformin, burformin) and 
insulin secretagogues (glibenclamide, tolbutamide) have been commonly used over the past few 




Metformin, a biguanide, is considered to be the first drug of choice in the treatment of T2D and it 
is taken by approximately 120 million people worldwide (Viollet et al., 2012), and it is 
considered to be beneficial for patients with non-obese T2D (Vaag and Lund, 2007) (Figure 1.9). 
It plays a role in decreasing the absorption rate of glucose in the small intestines, increasing 
peripheral glucose uptake in cells, decreasing plasma free fatty acid concentrations and inhibiting 
gluconeogenesis. All of these process requires the activation of AMP-activated protein kinase 
(AMPK) which is fundamental towards the mechanism of action of metformin (Viollet and 
Foretz, 2013; Grzybowska et al., 2011) by improving insulin sensitivity due to its beneficial 
effects towards tyrosine kinase activity and insulin receptor expression (Gunton et al., 2003). 
 
The mitochondria is considered to be the primary target site of metformin and it assumed to play 
a role in controlling energy homeostasis. Several studies have reported that metformin causes a 
mild inhibition on the mitochondrial respiratory chain complex 1 which results in a reduced 
hepatic energy state thus leading to a reduction in hepatic glucose production. This causes the 
activation of AMPK that plays a vital role in the mechanism of action of metformin (Viollet and 
Foretz, 2013). Recently, it has been reported that metformin antagonizes the signaling pathways 
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of glucagon by causing an over accumulation of AMP which leads to the inhibition of adenylate 
cyclase and causes a decrease in cAMP levels (Miller et al., 2013). 
 
Figure 1.9: The chemical structure of metformin (Copied without permission from Kalariya et 
al., 2012). 
Metformin has the ability to reduce fat accumulation in liver, lower both microvascular and 
macrovascular complications of T2D (Viollet et al., 2012), and does not promote hypoglycemia 
and weight gain (Campbell et al., 1996). In 2001, Maida et al. reported that metformin increases 
the levels of glucagon-like peptide-1 and promotes the gene expression of the islet incretin 
receptor (Maida et al, 2011). Metformin plays a vital role in improving lipid metabolism and 





Glibenclamide, also known as glyburide, is a powerful second generation sulphonylurea drug 
that stimulates pancreatic insulin secretion and it is used in the treatment of T2D (Luzi and 
Pozza, 1997) (Figure 1.10). It inhibits the sulphonylurea receptor 1 (SUR1) in the pancreatic 
beta-cells which accounts for the inhibition of ATP-sensitive potassium channels. This causes 
cell membrane depolarization which leads to the opening of voltage-dependent calcium channel. 
As a result there is a substantial increase in intracellular calcium in the beta-cells which promotes 
the stimulation of insulin secretion (Serrano-Martin et al., 2006). When the beta-cells are 
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exposed to glibenclamide for a short period (1 hour) they show an increase in sensitivity to 
glucose which leads to the secretion of insulin (Patanè et al., 2000).  
 
Figure 1.10: The chemical structure of glibenclamide (Copied without permission from Jiang 
et al., 2009). 
In 2003, Lehtihet et al. reported that glibenclamide has the ability to inhibit pancreatic islet 
carnitine palmitoyltransferase 1 (CPT) activity which causes an increase in protein kinase C-
dependent insulin exocytosis. Chronic CPT inhibition occurs due to the over accumulation of 
glibenclamide in the pancreatic islets which accounts for the over stimulation of insulin release 
thus leading to a state of hypoglycemia that is seen in some diabetic patients (Lehtihet et al., 
2003). In the liver, glibenclamide increases the rate of glycogen synthesis, inhibits 
glycogenolysis and suppresses gluconeogenesis. This results in an increase in fructose 2,6-
biphosphate levels thereby reducing the rate of glucose formation (Caro, 1990). Glibenclamide 
was found to increase the content of glucose transporters (GLUT) in the plasma membrane and 
stimulate glucose uptake in L6 skeletal muscle cells. It stimulated the synthesis of GLUT 1 but  
not GLUT 3 and GLUT 4 (Tsiani et al., 1995).  
Plant derived phytochemicals namely caffeine also possess anti-diabetic activities and pancreatic 
beta-cell protective effects as seen with commercially available anti-diabetic drugs (Kagami et 





1.6 Protective effects of caffeine towards the pancreatic beta-cells and T2D 
 
Caffeine (1,3,7-trimethylxanthine) is a methylxanthine alkaloid that acts as a stimulant drug and 
is one of the most commonly consumed dietary ingredient globally. It is normally consumed by 
humans in infusions such as coffee, tea, soft drinks and energy drinks and it is absorbed and 
eliminated from the body rapidly since it has a half-life of 5 hours (Heckman et al., 2010). 
Caffeine acts as a central nervous system stimulant which reduces fatigue, increases physical 
endurance and enhances mental alertness and concentration in humans (Daly, 2007). It is found 
in fruits, leaves and beans of many plants. The primary sources of caffeine around the world are 
tea leaves (Camelia siniensis) and roasted coffee beans (Coffea Arabica and Coffea robust) 
(Heckman et al., 2010). After caffeine is ingested, it is quickly absorbed from the gastrointestinal 
tract into the blood stream and in the liver it is completely metabolized (99%) by the cytochrome 
P450 oxidase enzyme system to form three major metabolites namely paraxanthine (84%), 
theobromine (12%) and theophylline (4%) (Heckman et al., 2010) (Figure 1.11). Paraxanthine 
has been reported to increase the rate of lipolysis which causes an increase in free fatty acids and 




Figure 1.11: Chemical structures of caffeine and its three metabolites namely 




Several reports have shown that consumption of coffee or caffeine containing drinks are 
associated with the reduction of T2D related symptoms and promotes weight loss (Bhupathiraju 
et al., 2013; Oka, 2007; van Dam and Hu, 2005; Whitehead and White, 2013; Keijzers et al., 
2002). In 2007, Park et al. found that long term caffeine consumption improves glucose 
homeostasis by enhancing insulinotropic action via islet insulin/ insulin-like growth factor 1. 
Moreover, caffeine improved peripheral glucose utilization with insulin sensitivity, improved 
insulin secretion and increased glucokinase expression as well as increased pancreatic beta-cell 
mass by increased proliferation (Park et al., 2007). In Spontaneously Diabetic KK-Ay Mice, both 
coffee and caffeine ameliorated the expression of adipocytokines, fatty liver and hyperglycemia 
(Yamauchi et al., 2010). Caffeine has beneficial effects on peripheral insulin sensitivity (Moisey 
et al., 2008) and has neuroprotective effects in STZ-induced diabetic rats by preventing synaptic 
degradation and astrogliosis in the brain which is usually caused by hyperglycemia (Duarte et al., 
2009). 
 
It is postulated that caffeine has the ability to suppress tissue-degenerating diseases namely T2D 
due to its immunomodulatory actions (Kagami et al., 2008). Its suppressive effects is due to its 
ability to inhibit adenosine monophosphate phosphodiesterase (cAMP-PDE) which leads to an 
increase in intracellular cAMP concentrations (Horrigan et al., 2006). Intracellular accumulation 
of cAMP enhances glucose regulation in the pancreatic beta-cells and liver (van Dam and Hu, 
2005) by activating the cAMP-responding element-binding protein which results in an increase 
in IRS-2 expression. This leads to an improved glucose homeostasis by enhancing insulin and 
insulin-like growth factor 1(IGF-1) signaling in the islets. This insulin signaling process occurs 
through the activation of tyrosine phosphorylation which activates Akt that is located 
downstream of IRS-2 (Jhala et al., 2003; Hennige et al., 2003; Withers et al., 1999). In STZ-
induced rats, bladder dysfunctions was improved by caffeine administration since it increased 
intracellular cAMP concentrations in the lower urinary tract (Chao-ran et al., 2006).  
Kagami et al. (2008) also observed that caffeine has a potent pancreatic beta-cell protecting 
effect in rats. Seven-week-old male Wistar rats were given intraperitoneal injections of caffeine 
at 10, 50, and 100 mg/kg body weight and after 15 minutes they were injected with 65 mg/kg 
body weight STZ. The control groups and diabetic groups were administered with saline and 
after 15 minutes citrate buffer and STZ were given respectively. The experiment was conducted 
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over a one week period only. The oral glucose tolerance test revealed abnormalities in glucose 
tolerance and insulin responsiveness in the diabetic groups which was evident by the high plasma 
glucose levels, conversely, the caffeine pretreatment groups showed much better glucose 
tolerance and reduced glucose levels compared to the diabetic group. Caffeine pretreatment did 
not recover the  plasma insulin levels which was reduced by streptozotocin injection, however, 
the pancreatic insulin content was significantly recovered by caffeine pretreatment at 100 mg/kg 
body weight (P < 0.01) (Kagami et al., 2008). 
 
Hence, caffeine can be a suitable compound to induce the non-obese animal model of T2D 
through partially protecting the pancreatic beta-cells and inducing moderate hyperglycaemia via 
partially protecting pancreatic beta-cell damage when injected in combination with STZ.  
 
1.7 Problem identification  
Animal models have been developed to closely resemble human T2D and this have led the 
cornerstone for powerful insights and understanding towards anti-diabetic drug discovery and to 
understand the etiology and pathophysiology behind this insidious disease (Srinivasan and 
Ramarao, 2007). Rodents (rats and mice) and non-rodents (pigs, dogs, monkeys) are used to 
develop diabetic animal models (Srinivasan and Ramarao, 2007). Non-rodent models show close 
similarities to human T2D in contrast to rodent models , however, they are expensive to develop 
and maintain and the development of the disease takes a longer time period (Daneshgari et al., 
2009). Almost 85% of all animal models are developed using rodents particularly rats (Wilson 
and Islam, 2012) due to their short generation time (Chen and Wang, 2005), smaller size, 
tranquil behavior, ease of handling, omnivorous nature and low maintenance costs (Islam and 
Loots, 2009).  
As discussed in the beginning section of this chapter, to date, numerous animal models of T2D 
have been developed and they each have both advantages and limitations in their use. Two major 
types of models are present for T2D research, namely genetic models and non-genetic models 
however none of them have all the pathological aspects of T2D seen in humans (Masiello et al., 
1998). These models of T2D are also classified as either obese or non-obese model. Although a 
number of genetic and non-genetic models of obesity related T2D have been developed in last 
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few decades (Islam and Loots, 2009), the number of genetic and non-genetic models of non-
obese T2D are very scanty, despite the millions of people that are suffering from non-obese T2D 
in the different parts of the world particularly in Far East Asia (Nakamura et al., 2006), Africa 
(Steyn et al., 2004; Olatunbosun et al., 2000) and in some European countries (Alvarsson et al., 
2005). 
Previously, either partial pancreatectomy or neonatal streptozotocin injection has been used as a 
major approach for the development of non-obese T2D animal model (Bonner-Weir et al., 1981; 
Weir et al., 1986; Portha et al., 1989). Some spontaneously induced genetic models of T2D have 
also been developed at a later stage (Portha et al., 1991; Movassat et al., 1995). These models 
have been developed to mainly display features of glucose insensitivity which actually does not 
appear in patients with non-obese T2D (Masiello et al., 1998). Hence, this model cannot be used 
to study the hypoglycemic effect of anti-diabetic drugs, foods or natural products. Using a 
similar approach, Nakamura et al. (2006) developed a non-obese T2D model in a genetic strain 
(C57BL/6J) of mice, which are not widely available, highly expensive, and hence, not suitable 
for routine pharmacological screening (Nakamura et al., 2006).  
Currently existing models of T2D show features of overweight, obesity, glucose insensitivity and 
insulin resistance, however, these features are not seen in patients with non-obese T2D (Vaag 
and Lund, 2007; Nakamura et al., 2006; Masiello et al., 1998). Although genetic models are 
useful for studying chronic diabetic complications, they are very expensive and not widely 
available to researchers in developing countries where funding and resources are limited (Islam 
and Loots, 2009). On the other hand, non-genetic models are widely available, easy to develop 
and highly cost-effective thereby making those more suitable for T2D research (Wilson and 
Islam, 2012) however many of them do not show similarities with human clinical conditions 
(Masiello et al., 1998) and majority of them resemble features of T1D (Winzel and Ahrén, 
2004). 
1.8 Aims and objectives 
Hence, the aim of the present study was to develop an alternative chemically-induced non-obese 
non-genetic rat model of T2D that closely resembles the clinical pathogenesis seen in humans as 
well as triumph over the disadvantages of currently available models. This model can be user-
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friendly, cheap to develop, suitable for pharmacological screening of drugs and can be developed 
in any animal laboratory worldwide with minimum facilities especially developing countries 
where funding and resources are limited. This animal model was developed using male Sprague-
Dawley rats, STZ to induce diabetes and respective dosages of caffeine which have been 
reported to have pancreatic beta-cell protecting activities. Metformin (an insulin sensitizer) and 
glibenclamide (an insulin secretagogue) are the two anti-diabetic drugs that were used to validate 




















MATERIALS AND METHODS 
2.1 Chemicals and materials 
Streptozotocin (STZ) (> 98%) and Caffeine (Sigma Aldrich, St. Louis, MO, USA) were 
purchased from Capital Lab Supplies cc, Durban, South Africa. Glibenclamide (Pharmacare Ltd., 
Durban, South Africa) and Metformin (Austell Laboratories Pvt. Ltd., Johannesburg, South 
Africa) were purchased from Pharmed Ltd., Durban, South Africa. A portable Glucometer and 
blood glucose test strips (GlucoPlus Inc, Quebec, Canada) were purchased from a local 
pharmaceutical company to measure both fasting and non-fasting blood glucose levels. 
Biochemical test kits were purchased (lipid profiles, enzymes, fructosamine, urea and creatinine) 
from a local company (Replamed Ltd., Centurion, South Africa). 
Dipotassium hydrogen phosphate anhydrous, Triton X-100, Sodium azide, 100% Acetic acid, 
Tert-butyl hydroperoxidase, Trizma hydrochloride, Sodium phosphate dibasic, 6-
Hydroxydopamine hydrobromide, L-Glutathione oxized, Glutathione solution, Sodium 
bicarbonate, Nicotinamide adenine dinucleotide phosphate solution, and Diethylenetriamine-
pentaacetic acid were purchased from Sigma Aldrich, Germany. Potassium dihydrogen 
orthophosphate, Sodium hydroxide pellets, Sodium dihydrogen orthophosphate, EDTA 
disodium, Sodium lauryl sulphate, 70% Perchloric acid, 2-Thiobarbituric acid, 30% Hydrogen 
peroxide, and Malondialdehydebis-(dimethyl acetal) were purchased from Merck (Pty) Ltd., 
Durban, South Africa.  
2.2 Animals, housing and feeding 
 
Six-week-old male Sprague-Dawley rats were procured from the Biomedical Resource Unit 
(BRU) at the Westville Campus of the University of KwaZulu-Natal (UKZN), Durban, South 
Africa. Animals with a mean body weight (BW) of 209.16 ± 19.75 g were randomly subdivided 
into 6 groups of 10 animals in each group as follows: Normal Control (NC), Diabetic Control 
(DBC), Caffeine 5 mg/kg BW + STZ (CAF5), Caffeine 10 mg/kg BW + STZ (CAF10), Caffeine 
20 mg/kg BW + STZ (CAF20) and, Caffeine 40 mg/kg BW + STZ (CAF40). Animals were 
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housed as two per polycarbonated cage in a temperature and humidity controlled room (23 ± 1 
ºC, 40-60% humidity) with a 12 hour light-dark cycle. The animals were fed a commercially 
available rat pellet diet and normal drinking water ad libitum throughout the 13 weeks 
experimental period. They were maintained according to the rules and regulations of the 
Experimental Animal Ethics Committee of the University of KwaZulu-Natal (Ethical approval 
number: 072/12/Animal). 
 
2.3 Induction of diabetes 
 
 2.3.1 Preparation of citrate buffer, caffeine, saline and STZ solutions 
 
Citrate buffer (0.1 M, pH 4.4): To prepare 0.1 M citrate buffer (pH 4.4), 1.92 g of citric acid 
crystals (M.W. of 192.12 g/mol, Sigma Addrich, St. Louis, MO, USA) and 2.94 g of sodium 
citrate dehydrate (M.W. of 294.10 g/mol, BDH Merck Ltd., Poole, England) were separately 
dissolved in 100 ml of distilled water for each. Then, these two solutions were mixed together to 
adjust the pH 4.4 by using a pH meter (SCHOTT Instruments, Deutschland, Germany). 
 
Normal saline (0.9% NaCl) solution: A 0.9 g of sodium chloride (M.W. of 58.44 g/mol, Merck 
Chemicals (PTY) LTD) was dissolved in 100 ml of distilled water. 
 
STZ solution: A 800 mg of STZ (M.w. of 265.22 g/mol) was dissolved in 40 ml of citrate buffer 
(20 mg/ml) and administered at 65 mg/kg BW to the rats. 
 
Caffeine solutions: The 30, 60, 120 and 240 mg of caffeine (M.W. of 194,19 g/mol) were each 
dissolved in 15 ml of saline and were administered to the rats at 5, 10, 20 and 40 mg/kg BW 
respectively. 
 
 2.3.2 Method 
 
Diabetes was induced in all animal groups except the NC group of overnight fasted animals 
(fasted for 12 hours) by an injection (i.p.) of STZ (65 mg/kg BW) dissolved in 0.1 M citrate 
buffer (pH 4.4) 15 minutes after the injection (i.p.) of the respective dosages of Caffeine (5, 10, 
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20 and 40 mg/kg BW) dissolved in normal physiological saline (0.9% NaCl). Saline was injected 
(i.p.) to the animals in NC and DBC groups only instead of caffeine and citrate buffer was 
injected to the animals in NC group only instead of STZ. Caffeine pretreatment at the above 
mentioned dosages were done before STZ administration since caffeine has protective effects 
towards the toxic effects of STZ on the pancreatic beta-cells (Kagami et al., 2008).  
 
Table 2.1: Summary of treatment given to the different animal groups (i.p.) 
 
Animal Groups 0 minutes  15 minutes 
NC Saline Citrate buffer 
DBC Saline  STZ  
CAF5 Caffeine at 5 mg/kg BW STZ 
CAF10 Caffeine at 10 mg/kg BW STZ 
CAF20 Caffeine at 20 mg/kg BW STZ 
CAF40 Caffeine at 40 mg/kg BW STZ 
 
NC: Normal Control; DBC: Diabetic Control; CAF5: Caffeine 5 mg/kg BW + STZ; CAF10: 
Caffeine 10 mg/kg BW + STZ; CAF20: Caffeine 20 mg/kg BW + STZ; CAF40: Caffeine 40 
mg/kg BW + STZ. 
 
2.4 Confirmation of diabetes and exclusion of animals 
 
One week after the caffeine and STZ injections, the animals were fasted for 3 hours, the blood 
was collected from the tail vein (5-10 µl) and non-fasting blood glucose (NFBG) levels were 
measured by using a portable glucometer with a maximum measuring capacity of 600 mg/dl. 
Animals with NFBG > 300 mg/dl were considered as diabetic and animals with blood glucose 





2.5 Weekly blood glucose 
 
Initially, NFBG of all animal groups was measured for the first 3 weeks, however since the blood 
glucose levels of some animals were higher than 600 mg/dl the measurement was switched from 
non-fasting to fasting after this period.  
 
2.6 Food and fluid intake, weekly body weight and exclusion of animal groups 
 
Daily food and water intake and weekly BW changes were measured during the entire 
experimental period. Due to the severity of diabetes, the animals in the CAF5 and CAF10 groups 
were excluded from the experiment in the third week of the experimental period. These groups 
had blood glucose levels > 500 mg/dl and in many cases > 600 mg/dl, and displayed features 
more of T1D. The remaining experiment was continued with the NC, DBC, CAF20 and CAF40 
groups only. 
 
2.7 Oral glucose tolerance test (OGTT) 
 
In order to assess the glucose tolerance ability, the OGTT was performed in week 11 of the 
experimental period. After an overnight fast for 12 hours, rats in all groups were orally dosed 
with a D-glucose solution (2.0 g/kg BW). This solution was prepared by dissolving 20 g of D-
glucose anhydrous (M.W. of 180,16 g/mol) (Associated Chemical Enterprises, Southdale, 
Johannesburg) in 20 ml distilled water (1 g/ml). The blood glucose concentrations were 
subsequently measured at 0 (just prior to oral glucose dosing), 30, 60, 90, and 120 minutes after 
the oral dosing of glucose. 
 
In order to give a clear quantitative indication of glucose intolerance in the different animal 
groups, area under the curve (AUC) values were calculated using the formula below: 
 
AUC = [(B2 + B1) / 2] × (A2 – A1) 
 
B1 and B2 = Initial and final blood glucose values (mg/dl) at a given time period respectively 
A1 and A2 = Initial and final time periods (min) respectively 
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Where: (A2 – A1) = (30 – 0), (60 – 30), (90 – 60) and (120 – 90)  
 (B2 + B1) = Blood glucose values at the above mentioned time periods 
 
2.8 Anti-diabetic drug response tests 
 
 2.8.1 Preparation of drugs and sodium carboxymethyl cellulose (Na-CMC) solutions 
 
Na-CMC solution (1%): A 1 g of Na-CMC was dissolved in 100 ml of distilled water. 
 
Glibenclamide solution: To prepare this solution, 30 mg of glibenclamide was dissolved in 15 
ml of Na-CMC (2 mg/ml) and administered to rats at 5 mg/kg BW. 
 
Metformin solution: To prepare this solution, 2000 mg of metformin was dissolved in 16 ml of 
Na-CMC (125 mg/ml) and administered to rats at 500 mg/kg BW.  
 
 2.8.2 Method 
 
In order to validate the newly developed caffeine-STZ-injected rat model for its suitability in 
screening drugs for anti-diabetic activities, the anti-diabetic drug response tests were performed 
by using two established and commonly used but mechanistically different anti-diabetic drugs; 
glibenclamide (sulphonylurea), an insulin secretogogue and metformin (biguanide), an insulin 
sensitizer. These tests were performed at week 5 (glibenclamide) and 7 (metformin) of the 
experimental period, respectively, with 2 weeks washout period to avoid any interference from 
the agents between tests. To perform these tests, animals in the CAF20 and CAF40 groups were 
fasted for 3 hours and each group was further subdivided into 2 groups namely control (CAF20 
and CAF40) and treatment (CAF20/CAF40-Glibenclamide and CAF20/CAF40-Metformin) with 
a similar mean BW. The control groups were orally administered with a 1% sodium 
carboxymethyl cellulose (Na-CMC) (Sigma-Aldrich, St. Louis, MO, USA) solution only while 
the treatment groups received either a single oral dose of glibenclamide (5 mg/kg BW) or 
metformin (500 mg/kg BW) dissolved in 1% Na-CMC, which was used as a vehicle for the 
drugs and has no physiological effects. For both these tests, the blood glucose concentration of 
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each animal was measured at 0 (just prior to oral dosing of drug or Na-CMC), 30, 60, 120 and 
180 minutes post oral ingestion of the drug. 
 
In order to give a clear quantitative indication of glucose intolerance in the different animal 
groups, area under the curve (AUC) values were calculated using the formula below: 
 
AUC = [(B2 + B1) / 2] × (A2 – A1) 
 
B1 and B2 = Initial and final blood glucose values (mg/dl) at a given time period respectively 
A1 and A2 = Initial and final time periods (min) respectively 
 
Where: (A2 – A1) = (30 – 0), (60 – 30), (120 – 60) and (180 – 120)  
 (B2 + B1) = Blood glucose values at the above mentioned time periods 
 
2.9 Collection of blood and tissue samples 
 
At the end of the 13 week experimental period, the final BW and FBG of overnight fasted 
animals were recorded, and were then euthanized by halothane anaesthesia. Blood was collected 
through cardiac puncture using a 21G needle and syringe, placed in normal tubes, left on ice for 
3 hours to coagulate and then centrifuged at 3000 rpm for 15 minutes. Hereafter, serum was 
collected, placed in microtubes and stored at -30 oC until further analysis. The liver, heart, 
kidney and pancreas of each animal was collected, washed with 0.9% saline, wiped, weighed and 
preserved at -30 oC for subsequent analysis. A small piece of liver, heart, kidney and pancreatic 
tissues from each animal was taken, placed in a 10% neutral buffered formalin solution and 
preserved at room temperature for histopathological studies. The neutral buffered formalin of 
each tissue sample was replaced weekly during the entire preservation period. 
 
2.10 Serum analysis for lipid profiles, enzymes, fructosamine, creatinine and urea 
 
An Automated Chemistry Analyzer (LabMax Plenno, Costa Brava, Brazil) and biochemical test 
kits were used to determine the concentration of total cholesterol (TC), triglycerides (TG), high 
density lipoproteins (HDL) cholesterol, low density lipoproteins (LDL) cholesterol, lactate 
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dehydrogenase (LDH), aspartate transaminase (ASAT), alanine transaminase (ALAT), alkaline 
phosphatase (ALP), creatine kinase (CK-MB), fructosamine, creatinine and urea in the serum 
samples. 
 
 2.10.1 Principles for TC, TG, HDL and LDL cholesterol determination 
 
 Total cholesterol (TC): 
 
For total cholesterol (TC) determination, cholesterol esterase hydrolyzes cholesterol esters to 
yield fatty acids and cholesterol. 
 
                                                         Cholesterol esterase 
Cholesterol esters                                                Cholesterol + Fatty acids 
 
Cholesterol oxidase then oxidizes the free cholesterol to cholest-4-en-one and hydrogen 
peroxide. 
                                                       Cholesterol oxidase 
   Cholesterol + O2                                                              Cholest-4-en-one + H2O2 
 
Lastly, phenol and 4-aminoantipyrine are oxized by peroxidase to yield quinoneimine which has 
a maximum absorption at wavelength 500 nm. The intensity of the pink colour, due to the end 
point reaction, is directly proportional to the concentration of cholesterol in the serum samples. 
 
                                                                                 Peroxidase 
2H2O2+ Phenol + 4-Aminoantipyrine                                           Quinoneimine + 4H2O 
 
 Triglyceride (TG): 
 
For triglyceride (TG) determination, triglycerides are hydrolysed by lipoprotein lipase to yield 
glycerol which in turn is converted to glycerol-3-phosphate by glycerolkinase and further 





                                                           Lipoprotein lipase 
       Triglyceride                                             Glycerol + Fatty acids 
 
                                                  Glycerolkinase / Mg2+ 
Glycerol + ATP                                                 Glycerol-3-phosphate + ADP 
 
                                                      Glycerol-3-phosphate oxidase 
Glycerol-3-phosphate + O2                                                                            Dihydroxyacetone + H2O2 
 
This is followed by a coupled reaction involving 4-chlorophenol, 4-aminoantipyrine and 
hydrogen peroxide that is catalysed by peroxidase thus yielding a quinoneimine which has a 
maximum absorbance at 505 nm. The intensity of the pink colour produced is proportional to the 
triglyceride concentration in the serum sample. 
 
                                                                                       Peroxidase 




The HDL cholesterol test involves the selective precipitation of LDL cholesterol and very low 
density lipoproteins (VLDL) cholesterols from the serum samples using phosphotungstic acid 
and magnesium chloride. This is obtained by centrifugation and the concentration of HDL 
cholesterol in the serum samples is measured in the resulting supernatant using the total 




The concentration of LDL cholesterol in the serum samples were determined using the following 
formular below: 
 
LDL cholesterol = {Total cholesterol – (HDL cholesterol + VLDL cholesterol*)} 
*VLDL cholesterol = Triglycerides / 5 
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 2.10.2 Principles for LDH, ALP, CK-MB, ASAT and ALAT determination 
 
 Lactate dehydrogenase (LDH): 
 
Lactate dehydrogenase (LDH) catalyzes the lactate-pyruvate reversible reaction in the presence 
of NAD+ that leads to the formation of NADH. The amount of NADH produced is proportional 
to the LDH enzymatic activity and the red coloured formazan produced is measured at an 
absorbance of 405 nm.  
 
 
                                                  NAD+           NADH + H+ 
                                                                                             2H+ + 2e- 
                                                              
Lactate                                     Pyruvate 
                                                             Lactate dehydrogenase 
 
 Alkaline phosphatase (ALP):  
 
For alkaline phosphatase (ALP) determination, ALP hydrolyzes p-nitrophenylphosphate to yield 
p-nitrophenol and inorganic phosphate (Pi) in an alkaline pH solution. The amount of p-
nitrophenol formed is directly proportional to the activity of ALP enzymes in the serum samples 
and absorbance readings are measured at 405 nm. 
 
                                                       Alkaline phosphatase 
p-Nitrophenylphosphate + H2O                                             p-Nitrophenol + inorganic phosphate 
 
 Creatine kinase (CK-MB): 
 
Creatine kinase-M (muscle type) B (brain type) (CK-MB) concentration in serum samples was 
determined by monitoring the amount of isoenzyme MB present. Samples are first incubated 
with a working reagent that contains a specific antibody for the CK-M subunit. This antibody 
completely inhibits the CK-M monomer enzymatic activity. As a result, the CK-B monomer is 
not inhibited and it was used for determining the concentration of CK-MB in samples. 
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Dephosphorylation of creatine phosphate, catalyzed by CK-B, yields ATP. Glucose reacts with 
ATP in the presence of hexokinase thus resulting in the formation of glucose-6-phosphate which 
in turn reacts with the enzyme glucose-6-phosphate dehydrogenase. This results in the formation 
of 6-phosphogluconate and NAD is reduced to NADH. An increase in absorbance at 340 nm is 
proportional to the activity of CK-MB in the samples. 
 
                                                                                CK-MB 
Creatine-phosphate + ADP                                   Creatine + ATP 
 
                                                          Hexokinase 
ATP + Glucose                                   ADP + Glucose-6-phosphate 
 
                                               Glucose-6-phosphate dehydrogenase 
Glucose-6-phosphate + NAD                                                            6-Phosphogluconate + NADH 
 
 Alanine transaminase (ALAT): 
 
Alanine transaminase (ALAT) plays a role in catalyzing the transfer of amino groups from 
alanine to ketoglutarate which yields pyruvate and glutamate. Lactate dehydrogenase reduces 
lactate to pyruvate and oxidizes NADH to NAD. Due to the oxidation of NADH, there is a 
reduction in absorbance at 340 nm and it is photometrically monitored since it is proportional to 
the activity of ALAT in the samples. 
 
                                                             Alanine transaminase 
L-Alanine + Ketoglutarate                                                        Pyruvate + L-Glutamate 
 
                                                                      Hexokinase 
Pyruvate + NADH                                          L-Lactate + NAD 
 
 Aspartate transaminase (ASAT): 
 
Aspartate transaminase (ASAT) plays a role in catalyzing the transfer of amino groups from 
aspartic acid to ketoglutarate which yields oxalacetate and glutamate. Malate dehydrogenase 
41 
 
reduces oxalacetate to malate and oxidizes NADH to NAD. Oxidation of NADH causes a 
reduction in absorbance at 340 nm and it is monitored photometrically since it is directly 
proportional to the activity of ASAT in the serum samples. 
 
                                                             Aspartate transaminase 
L-Aspartate + Ketoglutarate                                                    Oxalacetate + L-Glutamate 
                                                                 
                                                                 Malate dehydrogenase 
Oxalacetate + NADH                                                  Malate + NAD    
 




When glucose binds to the amino groups of proteins it yields a Schiff’s base (aldimine). It 
undergoes molecular rearrangements and transforms into fructosamine which is a stable 
ketoamine (Kyle et al., 2008). In this fixed-time kinetic method test, fructosamine is converted to 
an enolic form at an alkaline pH of 10.3 and reduces nitroblue tetrazolium (NBT) to a “purple 
formazan”. The difference in absorbance values at 530 nm after incubation of samples with nitro 
blue tetrazolium for 10 and 15 minutes is proportional to the fructosamine concentration in the 
serum samples. A bovine matrix calibrator that is calibrated with glycated polylysine is used. 
 
                                                                         pH 10.3 
Fructosamine (ketoamine form)              Fructosamine (alkenol form) 
  
         NBT2+ 
                                                   
                                     









Urea is determined by an enzymatic two-point, fixed-time kinetic method. This test involves the 
breakdown of urea to ammonia by the enzyme urease. Ammonia is then reacted with NADH and 
2-ketoglutarate, catalyzed by glutamate dehydrogenase, which leads to the oxidation of NADH 
to NAD and the formation of L-glutamate. The resulting reduction in absorbance is measured at 
340 nm and it is proportional to the concentration of urea in the samples. 
 
                                                                         Urease 
Urea + H2O2                                           NH3 + CO2 
 
               Glutamate dehydrogenase 




The concentration of creatinine in serum samples was determined by a colorimetric method. 
Creatinine reacts with alkaline picrate in an alkaline solution thus yielding a red complex that is 
measured photometrically at 510 nm. When acetic acid is added the pH decreases to 5.0 and the 
decomposition of creatinine picrate occurs. As a result, the chromogen derived colour remains 
unchanged and it is also read photometrically. The differences in absorbance measurements 
yields a true value of creatinine in the sample. 
 
    Alkaline pH 
Creatinine   +   Alkaline picrate                                     Creatinine – Picrate adduct 
 
 Acetic acid 
 






2.11 Serum insulin determination and calculation of HOMA-β and HOMA-IR scores  
 
 2.11.1 Principle 
An Ultrasensitive Rat Insulin ELISA kit (Mercodia, Uppsala, Sweden) was used to determine the 
concentration of insulin in the rat serum. This solid phase two-site enzyme immunoassay 
employs the use of two monoclonal antibodies which are directed against separate antigenic 
determinants on the insulin molecule. During incubation, insulin in the serum reacts with a 
peroxidase-conjugated anti-insulin antibody and it is followed by several washing steps that 
plays a role in removing any unbound enzyme-labelled antibodies. The bound conjugate is 
detected through the reaction with 3,3´,5,5´-tetramethylbenzidine (TMB) and this reaction is 
stopped by adding 0.5 M sulphuric acid thus leading to a colorimetric endpoint (yellow colour) 
that is read spectrophotometrically at 450 nm. Serum insulin standards were prepared by using a 
wide range of calibrators from calibrator 0-5 (concentration range from 0, 0.02, 0.05, 0.15, 0.4 
and 1.0 µg/l) and was used to plot a log-line standard curve to calculate the insulin 
concentrations in the samples. 
 2.11.2 Method 
In each well of the 96 wells plate, 50 µl of the serum samples or standards were added first and 
this was followed by 50 µl of enzyme conjugate being added. The samples and standards were 
left to incubate for 2 hours at room temperature on a mechanical shaker which was set at 150 
rpm. The solutions in each well were then aspirated, washed 6 times with 350 µl of 21X wash 
buffer and after the last washing step the plate was inverted on absorbent paper towel to dry. To 
each well, 200 µl of Substrate TMB was added and was left to incubate for 30 minutes at room 
temperature during which a blue colour developed. Hereafter, 50 µl of 0.5 M sulphuric acid was 
added to stop the reaction. The plate was shaken for 5 seconds and the absorbance was read in 
triplicate using a multiplate reader (Biorad-680, BIORAD Ltd., Japan) at 450 nm.  
The homeostatic model assessment (HOMA) method was used to quantify beta-cell function (β) 
and insulin resistance (IR) in the different animal groups. The HOMA model is used to 
determine the interaction between beta-cell function in response to glucose concentrations and 
insulin resistance. During insulin resistance, insulin has a weakened suppressive effect on hepatic 
glucose production, and a reduction in beta-cell functioning and a higher steady state insulin 
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levels (Fig. 1.3 and 1.4) are associated with higher insulin resistance (Matthews, 2001). HOMA-
β and HOMA-IR scores were calculated using FBG and fasting serum insulin concentrations at 
the end of the experimental period according to the formula below: 
HOMA-IR = [Insulin (U/l) × Blood glucose (mmol/l)] / 22.5 
HOMA-β = [20 × Insulin (U/l)] / [Blood glucose (mmol/l) – 3.5] 
Conversion factor: Insulin (1 U/l = 7.174 pmol/l)  
       : Blood glucose (1 mmol/l = 18 mg/dl) 
2.12 Liver glycogen determination 
 
2.12.1 Preparation of reagents and standards 
30% KOH saturated with Na2SO4 solution: A 30 g of KOH (M.W. of 56.11 g/mol) from 
Merck (Pty) Ltd., Durban, South Africa was dissolved in 100 ml of distilled water and Na2SO4 
(M.W. of 142.04 g/mol) (Saarchem PTY Ltd., Muldersdrift, South Africa) was added until it was 
unable to be saturated. 
5% phenol solution: A 5 g of phenol (M.W. of 94.11 g/mol) (MINEMA) from Capital Lab 
Supplies cc, Durban, South Africa was dissolved in 100 ml distilled water. 
Glycogen stock solution: A 5 mg of glycogen was dissolved in 5 ml distilled water (1 mg/ml). 
Glycogen standards: 5, 10, 20, 40, 80, 160, 320, and 640 µl of the glycogen stock solution were 
each diluted in 995, 990, 980, 960, 920, 840, 680, and 360 µl of distilled water respectively thus 
giving concentrations of 5, 10, 20, 40, 80, 160, 320, and 640 µg/ml respectively. 
 2.12.2 Method 
The liver glycogen levels were measured photometrically using the phenol-sulphuric acid 
method as described by Lo et al., (1970). Liver samples (< 1.0 g) were weighed, placed in the 
bottom of a screw-capped pyrex tube with forceps and then placed on ice. The samples were 
immersed with 1.5 ml of 30% potassium hydroxide (KOH) saturated with sodium sulphate 
(Na2SO4) and placed in a boiling water bath for 30 minutes or more for digestion of liver tissue. 
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The samples were then removed from the water bath and cooled on ice. Once cooled, 2 ml of 
95% ethanol was added and placed on ice for a further 30 minutes. The digested liver samples 
were then centrifuged at 840 x g (2812 rpm) for 30 minutes. The resulting supernatant was 
aspirated and the glycogen precipitate was dissolved in 3.0 ml of distilled water. A 100 µl of this 
solution was transferred into a clean test tube containing 900 µl of distilled water. Glycogen 
standards at concentrations of 5, 10, 20, 40, 80, 160, 320 and 640 µg/ml were prepared from a 
stock solution of 1 mg/ml glycogen (Oyster, Type II, Sigma-Aldrich, USA). The samples and 
standards were prepared in duplicates. Once the samples and standards were prepared, 1 ml of 
5% phenol was added followed by the rapid addition of 5 ml 96-98% sulphuric acid (H2SO4) 
(Shalom Laboratory Supplies, Durban, South Africa). The samples and standards were left to 
stand for 10 minutes at room temperature and the absorbance was then read at 490 nm using 
theUVmini-1240 UV-VIS spectrophotometer (SHIMADZU Corporation, Kyoto, Japan). 
Distilled water was used as a blank. The liver glycogen concentration was calculated from the 
glycogen standard curve.   
2.13 Preparation of tissue samples (liver, heart, kidney and pancreas) for the TBARS,  
        glutathione and antioxidative enzymes assays  
2.13.1 Preparation of homogenization buffer 
The homogenization buffer was prepared using a 50 mM mono-basic sodium phosphate solution 
(Solution A) and a 50 mM dibasic sodium phosphate solution (Solution B). Solution A was 
prepared by dissolving 2.99 g of mono-basic sodium phosphate (M.W. 119.98 g/mol) in 500 ml 
distilled water. Solution B was prepared by dissolving 3.53 g of dibasic sodium phosphate (M.W. 
141.56 g/mol) in 500 ml distilled water. A 0.5% (v/v) Triton X solution was prepared by adding 
5 ml of this solution to 1000 ml distilled water, and a required amount of this solution was added 
to the buffer before the adjustment of the pH. Solution A and Solution B were added until a pH 
of 7.5 was achieved using a Lab850 pH meter (SCHOTT Instruments, Deutschland, Germany). 







 2.13.2 Method 
Approximately 0.5 g of tissue sample was weighed and transferred into a mortar. Liquid nitrogen 
was added and the tissue was crushed into a powder form using a pestle. The crushed sample was 
mixed with 5 ml of ice cold homogenization buffer, transferred into a test tube and sonicated 
twice for 15 seconds each on ice cold water (sonicator used TRANSSONIC 460/H, Elma, 
Germany). The mixture was  transferred into a 2 ml microtube and centrifuged at 15000 rpm for 
10 minutes and at 4 °C using a microcentrifuge (Centrifuge 5424R, Eppendorf, Hamburg, 
Germany). The resulting supernatant was transferred into a new 2 ml microtube and stored at -20 
ºC for further analysis. 
2.14 Thiobarbituric acid reactive substances (TBARS) assay 
 
2.14.1 Preparation of reagents and malondialdehyde (MDA) standards 
 
8.1% sodium dodecyl sulphate (SDS) solution: A 1.62 g of SDS (M.W. of 288.38 g/mol) was 
dissolved in 20 ml of MiliQ water. 
 
20% acetic acid solution (pH 3.5): A 20 ml of acetic acid was diluted with 80 ml of MiliQ 
water and the solution was adjusted to a pH of 3.5 using sodium hydroxide.  
 
0.25% thiobarbituric acid (TBA) solution: A 0.625g of TBA (M.W. of 144.14g/mol) was 
dissolved in 250 ml of MiliQ water. 
MDA standards: A 0.1 M MDA was prepared by dissolving 82.93 µl of MDA stock with 5 ml 
MiliQ water. This solution was diluted 1000 times by diluting 0.05 ml of 0.1 M MDA with 49.95 
ml of MiliQ water and this was used to prepare the standards. MDA standards at concentrations 
of 0, 7.5, 15.0, 22.5, 30.0, 45.0 and 60.0 µM were prepared by diluting 0, 15, 30, 45, 60, 90 and 
120 µl of MDA with 200, 185, 170, 155, 140, 110 and 80 µl of MiliQ water respectively 
 
2.14.2 Principle and method 
  
The TBARS assay is used to determine the level of lipid peroxidation by determining the 
concentration of malondialdehyde (MDA) in biological samples. Thiobarbituric acid (TBA) 
47 
 
reacts with MDA in the sample to form a red fluorescent 1:2, MDA:TBA adduct that is measured 
spectrophotometrically at 532 nm.  
 
2 TBA       +       MDA                                   1:2, MDA – TBA adduct      +      H2O 
 
A 200 µl of tissue sample or MDA standards (0, 7.5, 15.0, 22.5, 30.0, 45.0 and 60.0 µM MDA) 
were placed into a screw cap test tube. Then 200 µl of 8.1% sodium dodecyl sulphate (SDS), 750 
µl of 20% acetic acid, 2 ml of 0.25% TBA and  850 µl of MiliQ water were added. The samples 
or standards were mixed, heated in a sandbath for 1 hour at 95 °C, cooled to room temperature 
and absorbance was measured at 532 nm. The concentration of MDA in the samples were 
extrapolated from the MDA standard curve and expressed in µM. 
 
2.15 Reduced glutathione (GSH) assay 
 
2.15.1 Preparation of reagents 
 
Ellman’s reagent: A 19.80 mg of 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) was dissolved in 
100 ml of 0.1% sodium nitrate. 
10% trichloroacetic acid (TCA): A 10 g of TCA (M.W. of 163.39 g/mol) was dissolved in 100 
ml distilled water. 
0.2 M sodium phosphate buffer: This buffer was prepared using a 0.2 M mono-basic sodium 
phosphate solution (Solution A) and a  0.2 M dibasic sodium phosphate solution (Solution B). 
Solution A was prepared by dissolving 23.99 g of mono-basic sodium phosphate (M.W. of 
119.98 g/mol) in 100 ml distilled water. Solution B was prepared by dissolving 28.31 g of 
dibasic sodium phosphate (M.W. of 141.56 g/mol) in 100 ml distilled water. Solution A and 
Solution B were added until a pH of 7.8 was achieved using a Lab850 pH meter (SCHOTT 
Instruments, Deutschland, Germany). The sodium phosphate buffer was stored in the refrigerator 






           2.15.2 Principle and method 
GSH is an antioxidant that prevents tissue damage caused by reactive oxygen species (Anthony 
et al., 2009). In this assay, Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid)) (DTNB) reacts 
with the sulfhydryl group of reduced glutathione (GSH) to form 5-thio-2-nitrobenzoic acid 
(TNB) which is a yellow coloured compound that is measured at 421 nm. The concentration of 
GSH in the sample is directly proportional to the rate of TNB production. 
                                                        Alkaline buffer 
DTNB2-     +     GSH                                         TNB2-     +     Mixed disulphide 
 
A 0.5 ml of tissue sample was mixed with 0.1 ml of 10% trichloroacetic acid (TCA) and 
centrifuged at 2000 rpm for 10 minutes at room temperature. In a clean test tube, 0.4 ml of the 
resulting supernatant or standards, 0.2 ml of Ellman’s reagent and 1.2 ml of 0.2 M sodium 
phosphate buffer (pH 7.8) was added and incubated for 40 minutes. Absorbance was read at 412 
nm. GSH standards were prepared at concentrations of 0.4, 0.2, 0.1, 0.05 and 0.025 mM and the 
concentration of GSH in the sample was extrapolated from the standard curve.  
2.16 Determination of total protein concentrations in tissue homogenates 
 
The Biuret method was used to determine the total protein concentration in the tissue samples. In 
the presence of an alkaline medium, the cupric ion forms a purple-violet complex with the amino 
moiety of two or more peptide bonds in the samples. Absorbance was read at 540 nm using an 
Automated Chemistry Analyzer (LabMax Plenno, Costa Brava, Brazil) and the concentration of 
protein in the sample was expressed as g/dl. 
2.17 Superoxide dismutase (SOD) enzyme assay  
 
2.17.1 Preparation of reagents  
  
SOD assay buffer: This buffer was prepared using a 50 mM mono-basic sodium phosphate 
solution (Solution A) and a 50 mM dibasic sodium phosphate solution (Solution B). Solution A 
was prepared by dissolving 2.99 g of mono-basic sodium phosphate (M.W. of 119.98 g/mol) in 
500 ml distilled water. Solution B was prepared by dissolving 3.53 g of dibasic sodium 
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phosphate (M.W. of 141.56 g/mol) in 500 ml distilled water. Solution A was steadily added to 
Solution B until a pH of 7.4 was achieved using a Lab850 pH meter (SCHOTT Instruments, 
Deutschland, Germany). The phosphate buffer was stored in the refrigerator until further use. 
 
1.6 mM 6-hydroxydopamine (6-HD): A 500 ml of MiliQ water and 3.25 ml of 70% (v/v) 
perchloric acid was added into a vacuum flask, connected to a negative pressure and sonicated 
until all the air bubbles was removed. To this degassed acid solution, 0.02 g of 6-HD (M.W. of 
250 g/mol) was added and the final volume was made up to 50 ml using the same acid solution. 
It was then wrapped with aluminium foil and stored on ice for immediate use 
 
0.1 mM diethylenetriaminepentaacetic acid (DETAPAC): A 0.8 mg of DETAPAC (M.W. of 
393.35 g/mol) was dissolved in 20 ml of SOD assay buffer and stored at -20 °C. 
 
 2.17.2 Principle and method 
 
In this assay, SOD catalyzes the dismutation of the superoxide ion to produce hydrogen 
peroxide, which in turn oxidizes 6-hydroxydopamine (6-HD) to form a coloured product. 
Diethylenetriaminepentaacetic acid (DETAPAC) was also used to prevent the aerobic oxidation 




                                             SOD 
              2O2-  +  2H+                                  H2O2  +  O2 
                                                                     + 
                                                                  6-HD                   p-Quinone  +  H2O 
                   
Based on the total protein determination, the tissue samples were diluted to a concentration of 
0.1 µg/µl using 50 mM sodium phosphate buffer (SOD assay buffer) (pH 7.4). In a 96 well plate, 
170 µl of 0.1 mM DETAPAC and 15 µl of the diluted tissue sample or SOD assay buffer (blank) 
was added. To this, 15 µl of 1.6 Mm 6-HD was added and mixed on a mechanical shaker for 1 
minute. The coloured product was measured at an absorbance of 492 nm for 5 minutes in 1 
minute interval using a multiplate absorbance reader. 
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SOD enzyme activity was calculated using the following formula: 
Activity = 1000 x [(A1-Ab)/ ε490 ] x 0.5 nmol/ min/ µg protein  
ε490 = Molar absorptivity at 490nm = 1.742 mM/ cm  
A1 and Ab = Reaction rate for sample and blank respectively.  
 
2.18 Catalase enzyme assay 
 
2.18.1 Preparation of reagents  
 
Catalase assay buffer (50 mM potassium phosphate buffer, pH 7.0): This buffer was 
prepared using a 50 mM mono-basic potassium phosphate solution (Solution A) and a 50 mM 
dibasic potassium phosphate solution (Solution B). Solution A was prepared by dissolving 1.70 g 
of mono-basic potassium phosphate (M.W. of 136.09 g/mol) in 250 ml distilled water. Solution 
B was prepared by dissolving 2.18 g of dibasic potassium phosphate (M.W. of 174.18 g/mol) in 
250 ml distilled water. Solution A was steadily added to Solution B until a pH of 7.0 was 
achieved using a Lab850 pH meter (SCHOTT Instruments, Deutschland, Germany). The 
phosphate buffer was stored in the refrigerator until further use. 
 
Hydrogen peroxide (H2O2) stock solution: The H2O2 solution was prepared by making up 68 
µl of 30% (v/v) hydrogen peroxide to a total volume of 20 ml using the catalase assay buffer.  
 
 2.18.2 Principle and method 
 
In this assay, catalase causes the decomposition of hydrogen peroxide to water and oxygen. The 
rate at which catalase decomposes hydrogen peroxide is proportional to the concentration of 
catalase in the sample. 
 
                                                                   Catalase 
2H2O2                                     2H2O  +  O2 
 
Based on the total protein determination, the tissue samples were diluted to a concentration of 
0.1 µg/µl using 50 mM sodium phosphate buffer (SOD assay buffer) (pH 7.4). In a UV quartz 
cuvette, 340 µl of catalase assay buffer and 150 µl of hydrogen peroxide stock solution was 
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added. After blanking the UV spectrophotometer with distilled water, the absorbance of the 
above prepared solution was read at 240 nm and the value was recorded (approximately 0.45). 
To this solution 10 µl of the diluted tissue sample was added and mixed. The linear decrease in 
absorbance was measured at 240 nm for at least 1 minute in every 15 seconds interval.  
 
Catalase enzyme activity was calculated using the following formula: 
Activity = (A/ ε240 ) x 0.5 µmol/ min/ µg protein 
A = Reaction rate for sample  
ε240 = Molar absorptivity at 240nm = 0.00394 mM/ cm. 
 
2.19 Glutathione reductase (GR) enzyme assay 
 
2.19.1 Preparation of reagents 
 
GR assay buffer (50 mM Tris. HCl and 1 mM EDTA solution, pH 8.0): A 0.394 g of Tris. 
HCl (M.W. of 157.60 g/mol) and 0.0186 g of EDTA (M.W. of 372.24 g/mol) was dissolved in 
50 ml of distilled water and the pH was adjusted to 8.0 using a sodium hydroxide solution. 
 
8 mM oxidized glutathione (GSSG) solution: A 0.05 g of GSSG (M.W. of 612.63 g/mol) was 
dissolved in 10 ml of distilled water. 
15 mM NADPH solution: A 10 ml of 0.1% (w/v) sodium hydrogen bicarbonate solution was 
prepared first by dissolving 0.01 g of sodium hydrogen bicarbonate (M.W. of 84.01 g/mol) in 10 
ml of distilled water. To a 2 ml of this prepared solution, a 0.025 g of NADPH (M.W. of 833.35 
g/mol) was dissolved. 
 
 
 2.19.2 Principle and method 
 
In this assay, glutathione reductase (GR) catalyzes the reduction of oxidized glutathione (GSSG) 
to GSH in the presence of NADPH. The activity of GR in the sample is proportional to the rate 
of oxidation of NADPH to NADP+ and reduction of GSSG to GSH which correlates to the linear 
decrease in absorbance at 340 nm.  
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                                                           Glutathione Reductase 
GSSG  +  2NADPH                                                           2GSH  +  2NADP+ 
 
Based on the total protein determination, the tissue samples were diluted to a concentration of 5-
10 mg/ml using the GR assay buffer (pH 8.0). In a 96 well plate, 10 µl of diluted tissue sample or 
GR assay buffer (blank) was added. Then, 221 µl of GR assay buffer, 38 µl of 8 mM GSSG 
solution and 10 µl of 15 mM NADPH solution was added and mixed for 1 minute using a 
mechanical shaker. A linear decrease in absorbance at 340 nm was measured instantaneously for 
5 minutes in 30 second intervals using a multi plate absorbance reader. 
 
 GR enzyme activity was calculated using the following formula:  
Activity =1000 x [(A1-Ab)/ ε340 ] x 0.5 nmol/ min/ µg  
ε340 = Molar absorptivity at 340nm = 6.22 mM/ cm  
A1 and Ab = Reaction rate for sample and blank respectively. 
 
2.20 Glutathione peroxidase (GPx) enzyme assay 
 
2.20.1 Preparation of reagents 
 
Assay buffer (50 mM potassium phosphate and 1 mM EDTA solution, pH 7.0): Prepared 
using a 50 mM mono-basic potassium phosphate solution (Solution A) and a 50 mM dibasic 
potassium phosphate solution (Solution B). Solution A was prepared by dissolving 1.70 g of 
mono-basic potassium phosphate (M.W. of 136.09 g/mol) in 250 ml distilled water. Solution B 
was prepared by dissolving 2.18 g of dibasic potassium phosphate (M.W. of 174.18 g/mol) in 
250 ml distilled water. Solution A was steadily added to Solution B until a pH of 7.0 was 
achieved using a Lab850 pH meter (SCHOTT Instruments, Deutschland, Germany). A 1 mM 
EDTA disodium salt (M.W. of 372.24 g/mol) solution was prepared by dissolving 0.037 g of this 
salt in 100 ml distilled water and it was added to the buffer prepared above. The pH of the buffer 





100 mM GSH solution: A 0.0614 g of GSH (M.W. of 307.32 g/mol) was dissolved in 2 ml 
distilled water. 
 
0.1 U/ml GR solution: A 1.7 µl of 187 U/ml (16 mg/ml) GR solution was diluted with 998 µl of 
assay buffer. 
 
12 mM tert-butylhydroperoxide (t-BHP): Prepared by making up 16 µl of 7.7 M t-BHP to 100 
ml using distilled water.  
 
1.5 mM H2O2 solution: Prepared by making up 2 µl of commercial 30% (v/v) H2O2 to 10 ml 
using distilled water. 
100 mM sodium azide solution: A 0.065 g of sodium azide (M.W. of 65.01 g/mol) was 
dissolved in 10 ml of distilled water. 
 
15 mM NADPH solution: A 10 ml of 0.1% (w/v) sodium hydrogen bicarbonate solution was 
prepared first by dissolving 0.01 g of sodium hydrogen bicarbonate (M.W. of 84.01 g/mol) in 10 
ml of distilled water. To 2 ml of this prepared solution, 0.025 g of NADPH (M.W. of 833.35 
g/mol) was dissolved. 
 
 2.20.2 Principle and method 
 
In this assay, glutathione peroxidase (GPx) oxidizes GSH to GSSG in the presence of hydrogen 
peroxide. The quantification of GPx activity in the sample was based on the ability of GR to 
catalyze GSSG back to GSH in the presence of an electron donor namely NADPH.  
 
                                                            Glutathione Peroxidase 
2GSH  +  H2O2                                                        GSSG  +  2H2O 
 
                                                            Glutathione Reductase 




Based on the total protein determination, the tissue samples were diluted to a concentration of 5-
10 mg/ml using the GR assay buffer (pH 8.0). In a 96 well plate, 10 µl of diluted tissue sample or 
homogenization buffer (blank) was added. Then, 420 µl of assay buffer, 5 µl of 100 mM GSH 
solution and 5 µl of 0.1 U/ml glutathione reductase was added. A 5 µl of 100 mM sodium azide 
solution was added to the diluted liver sample homogenates only to inhibit its catalase activity 
while 5 µl of distilled water was added to the heart, kidney and pancreas homogenates, and 
blank. Then, 5 µl of 15 mM NADPH solution was added and the tert-butylhydroperoxide (t-
BHP)-independent NADPH oxidation at absorbance of 340 nm was recorded for 3 minutes in 30 
seconds intervals for sample (A1) and blank (A1b) using a multi plate reader. The reaction was 
started with 50 µl of either 12 mM of t-BHP solution or 1.5 mM hydrogen peroxide solution 
(liver samples only) and mixed. The hydroperoxide-dependent linear NADPH oxidation at an 
absorbance of 340 nm was measured for 2 minutes in 30 seconds intervals for sample (A2) and 
blank (A2b) using a multi plate reader. 
 
GPx enzyme activity was calculated using the following formula: 
Activity =1000 x {[(A2-A1)-(A2b-A1b)]/ ε340 } x 0.5 nmol/ min/ µg  
ε340 = Molar absorptivity at 340nm = 6.22 mM/ cm  
A1 and A2 = Reaction rate for reaction 1 and 2 for sample respectively 
A1b and A2b = Reaction rate for reaction 1 and 2 for blank respectively. 
 
2.21 Histopathological examination of the liver, heart, kidney and pancreatic tissues 
 
The formalin preserved tissue samples were immersed in 40% ethanol for overnight (12 hours) 
and subsequently immersed in 60%, 80% and twice in 100% ethanol for 1 hour each in the 
following day. Tissue samples were then dried on filter paper, immersed twice in p-xylene with a 
time period of 1 hour each, dried on filter paper, immersed in paraffin wax and was left in an 
oven for an overnight period. Next day, the samples were removed from the wax, re-immersed in 
fresh wax, placed in an oven for 1 hour and were then embedded in paraffin wax. Sections of the 
wax embedded samples were cut into a size of 4 µm, placed in a warm water bath and “ribbons” 
of the wax-sample were placed on slides. The slides were placed on a hotplate to dry and then 
left to dry further at room temperature for an overnight period. The slides were deparaffinized 
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twice in p-xylene for 3 minutes each, rehydrated in 100%, 70% and 50% ethanol at 2 minutes 
each, and was kept in distilled water until ready for staining. Slides were then stained with 
hematoxylin for 3 minutes, rinsed with water, counterstained with eosin for 3 minutes, washed 
with water, dipped in 90% ethanol for 2 seconds, dried on filter paper and was immersed in p-
xylene until ready to cover by a coverslip. Finally, slides were dried on filter paper, mounted in 
DPX, cover-slipped and viewed under a light microscope (Olympus CKX41, Olympus, Japan) 
that was connected to a computer. 
 
2.22 Statistical analysis 
 
All data are presented as the mean ± SD. The data were analyzed by a statistical software 
package (IBM SPSS Statistics, Version 21, USA) using the Tukey-Kramer multiple range post 























3.1 Food and fluid intake 
 
Figure 3.1 shows the mean food and fluid intake per animal per day over the 13 week 
experimental period. Food and fluid intake of DBC, CAF20 and CAF40 groups were 
significantly higher (p < 0.05) compared to the NC group. However, the food and fluid intake of 
CAF20 and CAF40 groups were relatively lower compared to the DBC group (Fig. 3.1). 
 
 
Figure 3.1: Mean food intake (g) and fluid intake (ml) per animal per day over the 13 weeks 
experimental period. Data are shown as mean ± SD of 8-10 animals; a,bDifferent letters over the 
bars for a given parameter are significantly different from each other group of animals (Tukey’s 
multiple range post-hoc test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; CAF20: 
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57 
 
3.2. Body weight change 
 
Figure 3.2 shows the weekly BW change over the 13 week experimental period. All the animal 
groups had a similar mean initial BW at the beginning of the study however as soon as STZ was 
injected, the BW of the animals in the DBC, CAF20 and CAF40 groups were significantly 
reduced (p < 0.05) compared to the NC group throughout the experimental period. Although 
there were no significant differences in BW observed between the DBC, CAF20 and CAF40 
groups however the BW of CAF groups were relatively better compared to the DBC group (Fig. 
3.2). 
 
Figure 3.2: Mean body weight gain (g) over the 13 weeks experimental period. Data are shown 
as mean ± SD of 8-10 animals; a,bDifferent letters over the lines for a given week are 
significantly different from each other group of animals (Tukey’s multiple range post-hoc test, p 
< 0.05). NC: Normal Control; DBC: Diabetic Control; CAF20: Caffeine 20 mg/kg BW + STZ; 
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3.3. Weekly blood glucose 
 
Figure 3.3 shows the level of weekly blood glucose (BG) of different animal groups during the 
13 weeks experimental period. The BG of the DBC and CAF groups were significantly higher (p 
< 0.05) compared to the NC group however the BG of DBC group was significantly higher than 
the CAF groups. The NFBG was not significantly different in the first 3 weeks between the 
DBC, CAF20 and CAF40 groups, however the FBG levels of CAF groups were significantly 




Figure 3.3: Mean blood glucose (mg/dl) over the 13 weeks experimental period. Weeks 1-3 
indicate NFBG whilst weeks 4-13 indicate FBG levels in all groups. Data are shown as mean ± 
SD of 8-10 animals; a,b,cDifferent letters over the lines for a given week are significantly different 
from each other group of animals (Tukey’s multiple range post-hoc test, p < 0.05). NC: Normal 
Control; DBC: Diabetic Control; CAF20: Caffeine 20 mg/kg BW + STZ; CAF40: Caffeine 40 
mg/kg BW + STZ.  
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3.4 Oral glucose tolerance test (OGTT) 
 
The data for OGTT are presented in Figure 3.4 and Table 3.1. Two hours after the glucose 
administration, the BG levels of the DBC, CAF20 and CAF40 groups were significantly higher 
than the NC group. The BG levels of the CAF20 group after two hours was significantly lower (p 
< 0.05) than the DBC group and non-significantly lower compared to the CAF40 group while 
there were no significant differences between the DBC and CAF40 groups. After 60 minutes the 




Figure 3.4: Oral glucose tolerance test (OGTT) at week 11 of the 13 weeks experimental period. 
Data are shown as mean ± SD of 8-10 animals; a,b,cDifferent letters over the lines for a given time 
are significantly different from each other group of animals (Tukey’s multiple range post-hoc 
test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; CAF20: Caffeine 20 mg/kg BW + 






























Time after glucose ingestion (minutes) 
NC DBC CAF20 CAF40
60 
 
Table 3.1: Area under the curve (AUC) values for the OGTT at week 11 of the 13 weeks 
experimental period.  
 
Area under curve 
         (AUC) 
NC DBC CAF20 CAF40 
AUC 1 
(0-30 min) 
3466 ± 290a 15670 ± 1017b 13678 ± 363c 13433 ± 1367c 
AUC 2 
(30-60 min) 
3717 ± 452a 16922 ± 983b 15406 ± 535c 15161 ± 1278c 
AUC 3 
(60-90 min) 
3456 ± 495a 16925 ± 619b 14641 ± 1113c 15188 ± 1299c 
AUC 4 
(90-120 min) 
3277 ± 341a 16115 ± 1095b 13429 ± 1175c 14483 ± 1115c 
Total AUC 13918 ± 1330a 65634 ± 3357b 57155 ± 2961c 58268 ± 4301c 
 
Data are shown as mean ± SD of 8-10 animals; a,b,cValues with different superscript letters within 
a row are significantly different from each other group of animals (Tukey’s multiple range post-
hoc test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; CAF20: Caffeine 20 mg/kg 
BW + STZ; CAF40: Caffeine 40 mg/kg BW + STZ.  
 
 
3.5 Anti-diabetic drug response test 
 
 3.5.1 Glibenclamide 
 
Figure 3.5a and Table 3.2 highlights the results of the glibenclamide anti-diabetic drug response 
test on the CAF20 and CAF40 groups. The BG of the animals was significantly lowered at 60, 
120 and 180 mins after oral ingestion of glibenclamide in the CAF20 group, while the CAF40 
group only had significantly lowered blood glucose at 120 and 180 mins compared to the control 





Figure 3.5a: Effects of glibenclamide (5 mg/kg BW) on blood glucose of CAF20 and CAF40 
groups. Data are shown as mean ± SD of 8-10 animals; a,bDifferent letters over the lines for a 
given time are significantly different from each other (Tukey’s multiple range post-hoc test, p < 














































Table 3.2: Area under the curve (AUC) values for the glibenclamide anti-diabetic drug 
response test at week 5 of the 13 weeks experimental period.  
Area under curve 
(AUC) 
CAF20 
Control                 Drug 
CAF40 










16625 ± 413a 
 
14188 ± 1002b 
 
15573 ± 1142a 
 






33616 ± 1364a 
 
26609 ± 1541b 
 
31233 ± 2570a 
 






33805 ± 1657a 
 
27176 ± 1934b 
 
31719 ± 2838a 
 




100260 ± 2577a 
 
83296 ± 5851a 
 
94257 ± 7926a 
 
83086 ± 2493b 
 
Data are shown as mean ± SD of 5 animals; a,bValues with different superscript letters within a 
row are significantly different from each other group of animals (Tukey’s multiple range post-
hoc test, p < 0.05). CAF20: Caffeine 20 mg/kg BW + STZ; CAF40: Caffeine 40 mg/kg BW + 
STZ.  
 
 3.5.2 Metformin 
 
Figure 3.5b and Table 3.3 highlights the results of the metformin anti-diabetic drug response test 
on the CAF20 and CAF40 groups. In the case of metformin, both the CAF20 and CAF40 groups 
had a progressive decline of BG until 180 min when significant reductions were observed after 








Figure 3.5b: Effects of metformin (500 mg/kg BW) on blood glucose of CAF20 and CAF40 
groups. Data are shown as mean ± SD of 8-10 animals; a,bDifferent letters over the lines for a 
given time are significantly different from each other (Tukey’s multiple range post-hoc test, p < 

















































Table 3.3: Area under the curve (AUC) values for the metformin anti-diabetic drug 
response test at week 7 of the 13 weeks experimental period.  
 
Area under curve 
(AUC) 
CAF20 
Control                 Drug 
CAF40 
















33454 ± 1497a 21141 ± 2341b 32076 ± 3021a 24530 ± 2026b 
Total AUC 98343 ± 4894a 76876 ± 8362a 97027 ± 9576a 84120 ± 6586b 
 
Data are shown as mean ± SD of 5 animals; a,bValues with different superscript letters within a 
row are significantly different from each other group of animals (Tukey’s multiple range post-




3.6 Serum lipid profile 
 
Figure 3.6 shows the data for the serum lipid profile in different experimental groups. The level 
of serum triglycerides was significantly increased in all groups compared to the NC group 
whereas no significant differences were observed for total cholesterol and HDL-cholesterol 
among the animal groups. The DBC group had significantly higher LDL-cholesterol level 
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compared to all other groups only when no significant differences were observed between these 
groups (Fig. 3.6). 
 
 
Figure 3.6: Serum lipid profile in different animal groups at the end of the experimental period. 
Data are shown as mean ± SD of 8-10 animals; a,bDifferent letters over the bars for a given 
parameter are significantly different from each other group of animals (Tukey’s multiple range 
post-hoc test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; CAF20: Caffeine 20 
mg/kg BW + STZ; CAF40: Caffeine 40 mg/kg BW + STZ; HDL: high density lipoproteins; 
LDL: low density lipoproteins. 
 
3.7 Liver weights and liver glycogen 
The data for liver weights and liver glycogen levels are presented in Table 3.4. The NC group 
had a significantly higher liver weight compared to all other groups while relative liver weights 





























NC DBC CAF20 CAF40
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glycogen levels of DBC, CAF20 and CAF40 groups were also significantly higher than the NC 
groups (Tab. 3.4). 
 
Table 3.4: Liver weights and liver glycogen levels in different animal groups at the end of 
the 13 weeks experimental period.  
 
Rat group NC DBC CAF20 CAF40 
Liver weight (g) 13.33 ± 2.08a 8.50 ± 2.12b 8.94 ± 1.10b 7.48 ± 1.77b 
Relative liver weight (%)1 2.72 ± 0.19a 4.14 ± 0.70b 3.11 ± 0.24ab 3.65 ± 0.51b 
Liver glycogen (mg/g 
tissue) 
6.72 ± 0.9a 24.95 ± 1.60b 21.13 ± 3.84b 22.15 ± 2.09b 
 
Data are shown as mean ± SD of 8-10 animals; a,bValues with different superscript letters within 
a row are significantly different from each other group of animals (Tukey’s multiple range post-
hoc test, p < 0.05). 1Relative liver weight (%) = [(liver weight in grams / body weight in grams)] 
x 100. NC: Normal Control; DBC: Diabetic Control; CAF20: Caffeine 20 mg/kg BW + STZ; 
CAF40: Caffeine 40 mg/kg BW + STZ.   
 
 
3.8 Serum insulin, fructosamine, HOMA-IR and HOMA-β 
 
The data for serum insulin, fructosamine, and HOMA-IR and HOMA-β scores are presented in 
Table 3.5. Significantly higher (p < 0.05) serum insulin and lower fructosamine levels were 
observed in the DBC, CAF20 and CAF40 groups compared to the NC group, while DBC group 
had a lower insulin and higher fructosamine concentrations compared to the CAF20 and CAF40 
groups. The HOMA-IR and HOMA-β scores were significantly higher in the CAF20 and CAF40 
groups compared to the DBC group, which denotes more insulin resistance but better pancreatic 





Table 3.5: Serum insulin, fructosamine, and HOMA-IR and HOMA-β scores in different 




NC DBC CAF20 CAF40 
Insulin (pmol/l) 118.95 ±25.72a 9.16 ± 1.64c 25.81 ± 5.57b 21.53 ± 2.91b 
Fructosamine(µmol/l) 227 ± 14.18a 296.25 ± 6.96b 257 ± 19.81 c 279 ± 19.60bc 
HOMA-IR1 3.90 ± 1.01a 1.61 ± 0.28b 3.51 ± 0.73a 2.54 ± 0.43c 
HOMA-β2 120.32 ± 18.98a 1.03 ± 0.21b 3.90 ± 0.72c 2.77 ± 0.45c 
 
Data are shown as mean ± SD of 8-10 animals; a,b,cValues with different superscript letters within 
a row are significantly different from each other group of rats (Tukey’s multiple range post-hoc 
test, p < 0.05). 1HOMA-IR = [Insulin (U/l) × Blood glucose (mmol/l)] / 22.5; 2HOMA-β = [20 × 
Insulin (U/l)] / [Blood glucose (mmol/l) – 3.5]. NC: Normal Control; DBC: Diabetic Control; 
CAF20: Caffeine 20 mg/kg BW + STZ; CAF40: Caffeine 40 mg/kg BW + STZ; HOMA: 
homeostatic model assessment; IR: insulin resistance.  
 
 
3.9 Serum creatinine, urea, ASAT, ALAT, LDH, ALP and CK-MB 
 
The data for serum creatinine, urea, ASAT, ALAT, LDH, ALP and CK-MB levels are presented 
in Table 3.6. There were no significant difference in serum creatinine and ASAT levels, 
however, the ALAT, CK-MB and urea levels for the NC group was significantly lower compared 
to all other groups. The serum ALP levels for the NC group was significantly lowered compared 
to other groups, however, the DBC group was significantly higher compared to CAF40 group 
which in turn was significantly lower compared to CAF20 group. Results for serum LDH levels 
showed no significant differences between the NC and CAF20 groups, however, these groups 





Table 3.6: Serum creatinine, urea, ASAT, ALAT, LDH, ALP and CK-MB levels in 




NC DBC CAF20 CAF40 
Creatinine (mg/dl) 0.47 ± 0.07a 0.58 ± 0.06a 0.53 ± 0.05a 0.56 ± 0.07a 
Urea (mg/dl) 28.50 ± 4.60a 102.13 ± 28.53b  91.13 ± 24.16b 89.50 ± 24.28b 
ASAT (U/L) 88.70 ± 8.86a 139.75 ± 34.78b 121 ± 29.77ab 99.87 ± 26.91ab 
ALAT (U/L) 42.10 ± 10.47a 146.75 ± 31.37b 138.38 ± 33.79b 111.80± 29.84b 
LDH (U/L) 385.30 ± 37.01a 616.13 ± 72.26b 471.25 ± 97.10ab 512.10 ± 88.98b 
ALP (U/L) 83.10 ± 14.46a 713.75 ± 98.73c 624 ± 104.03 c 437.30± 88.84b 
CK-MB (U/L) 428 ± 83.53a 625.32 ± 62.85b 637.94 ± 82.58b 699.21 ± 99.20b 
 
Data are shown as mean ± SD of 8-10 animals; a,b,cValues with different superscript letters within 
a row are significantly different from each other group of rats (Tukey’s multiple range post-hoc 
test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; CAF20: Caffeine 20 mg/kg BW + 
STZ; CAF40: Caffeine 40 mg/kg BW + STZ; ASAT: aspartate transaminase; ALAT: alanine 




3.10 Thiobarbituric acid reactive substance (TBARS) assay 
 
The data for the TBARS are presented in Figure 3.7. The malondialdehyde (MDA) was used as 
an equivalent of TBARS during this assay The MDA concentrations were significantly higher in 
the DBC group compared to the NC group but relatively reduced in the CAF20 and CAF40 
groups compared to DBC group. The liver, heart, kidney and pancreas tissues of the CAF40 
group and the heart tissue of the CAF20 group had no significant differences when compared to 
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the NC group. Overall, no significant differences between the CAF20 and CAF40 groups were 
observed (Fig. 3.7).   
 
 
Figure 3.7: Malondialdehyde concentration in different animal groups at the end of the 
experimental period. Data are shown as mean ± SD of 8-10 animals; a,bDifferent letters over the 
bars for a given organ or sample are significantly different from each other group of animals 
(Tukey’s multiple range post-hoc test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; 
CAF20: Caffeine 20 mg/kg BW + STZ; CAF40: Caffeine 40 mg/kg BW + STZ; MDA: 
malondialdehyde. 
 
3.11 Reduced glutathione (GSH) assay 
 
Figure 3.8 highlights the results obtained for the GSH assay. The GSH concentrations in the NC 
group of all the tissues and serum samples were significantly increased compared to the DBC, 














































mentioned diabetic groups. The GSH levels in the CAF20 group for the liver and pancreas were 
relatively higher compared to the CAF40 group (Fig. 3.8).  
 
 
Figure 3.8: GSH concentration in different animal groups at the end of the experimental period. 
Data are shown as mean ± SD of 8-10 animals; a,bDifferent letters over the bars with different 
letters for a given parameter are significantly different from each other group of animals 
(Tukey’s multiple range post-hoc test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; 




3.12 Antioxidative enzyme assays 
 
 3.12.1 Catalase assay 
 
Figure 3.9a depicts the data obtained for the catalase assay. In all the samples, the catalase 
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The CAF20 group of the liver and serum samples had a significantly lower catalase activity 
compared to the DBC and CAF40 groups, however, relatively elevated in the heart, kidney and 
pancreas compared to the CAF40 group (Fig. 3.9a). 
 
 
Figure 3.9a: Catalase activity in different animal groups at the end of the experimental period. 
Data are shown as mean ± SD of 8-10 animals; a,bDifferent letters over the bars for a given organ 
or sample are significantly different from each other group of animals (Tukey’s multiple range 
post-hoc test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; CAF20: Caffeine 20 
mg/kg BW + STZ; CAF40: Caffeine 40 mg/kg BW + STZ. 
 
 3.12.2 Superoxide dismutase (SOD) assay 
 
The data for the SOD assay is illustrated in Figure 3.9b. The SOD enzyme activities of all tissues 
and sample from the diabetic groups were significantly increased in compared to the NC group. 
























































compared to the CAF20 group while the heart of the DBC group had a significantly elevated 
SOD activity compared to the caffeine groups (Fig. 3.9b). 
 
 
Figure 3.9b: Superoxide dismutase activity in different animal groups at the end of the 
experimental period. Data are shown as mean ± SD of 8-10 animals; a-dDifferent letters over the 
bars for a given organ or sample are significantly different from each other group of animals 
(Tukey’s multiple range post-hoc test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; 
CAF20: Caffeine 20 mg/kg BW + STZ; CAF40: Caffeine 40 mg/kg BW + STZ. 
 
 3.12.3 Glutathione reductase (GR) assay 
 
Figure 3.9c shows the results obtained for the GR assay. A mixed trend of GR activity was 
evident for all the different samples groups. The GR activity of the NC group was significantly 




























































Figure 3.9c: Glutathione reductase activity in different animal groups at the end of the 
experimental period. Data are shown as mean ± SD of 8-10 animals; a,b,cDifferent letters over the 
bars for a given organ or sample are significantly different from each other group of animals 
(Tukey’s multiple range post-hoc test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; 
CAF20: Caffeine 20 mg/kg BW + STZ; CAF40: Caffeine 40 mg/kg BW + STZ. 
 
  
3.12.4 Glutathione peroxidase (GPx) assay 
 
The data obtained for the GPx assay are shown in Figure 3.9d. As observed with the GR assay, a 
mixed trend GPx enzyme activity was observed. The GPx activity was significantly lower in the 
heart and serum samples and significantly higher in the kidney sample of CAF20 group  































































Figure 3.9d:  Glutathione activity in different animal groups at the end of the experimental 
period. Data are shown as mean ± SD of 8-10 animals; a,b,cDifferent letters over the bars for a 
given organ or sample are significantly different from each other group of animals (Tukey’s 
multiple range post-hoc test, p < 0.05). NC: Normal Control; DBC: Diabetic Control; CAF20: 



















































































3.13 Histopathological examination of the pancreatic, liver, heart and kidney tissues 
 
 3.13.1 Pancreatic tissues 
 
The slides for histopathological examination of the pancreatic tissues are presented in Figure 
3.10a. The slides revealed a reduced pancreatic beta-cell numbers in the DBC, CAF20 and 
CAF40 groups compared to the NC group. However, severe damage of pancreatic islets was seen 
in the DBC group with deformed beta-cells compared to the CAF20 and CAF40 groups, but 
better physiological shape with a substantial numbers of healthy beta-cells were remained in the 
CAF20 group compared to the CAF40 group (Fig. 3.10a). 
 
     
         
 
Figure 3.10a: Hisopathological examinations (40x) of the pancreatic islets of different animal 
groups at the end of the experimental period. Arrows indicating the morphology of pancreatic 
islets and β-cells. NC: Normal Control; DBC: Diabetic Control; CAF20: Caffeine 20 mg/kg BW 





 3.13.2 Liver tissues 
 
Histopathological examination of the liver tissues are presented in Figure 3.10b. The NC group 
displayed a normal physiological appearance and arrangement of the hepatocytes and they 
appeared to be bigger in size with no visible tissue damage while the DBC group had the most 
severe degeneration of the hepatocytes and vacuolization compared to the CAF20 and CAF40 
groups. Overall, the CAF20 group showed a morphologically healthier appearance of the 
hepatocytes compared to the CAF40 group (Fig. 3.10b). 
   
       
       
 
Figure 3.10b: Hisopathological examinations (20x) of the liver tissues of different animal 
groups at the end of the experimental period. NC: Normal Control; DBC: Diabetic Control; 






3.13.3  Heart tissues 
 
Histopathological examination of the cardiac (heart) tissues are presented in Figure 3.10c. The 
NC group displayed a normal and healthy myocardium morphology, however, the DBC, CAF20 
and CAF40 groups had heart tissue damage as indicated by myofibril loss and an increase in 
cytoplasmic vacuolization. Lesions in the myocardium of the CAF20 and CAF40 groups was 
significantly reduced due to caffeine pretreatment compared to the DBC group which had an 
unhealthy appearance of the nuclei and the severity of necrosis in the cardiac muscle was 
detrimentally high (Fig. 3.10c). 
 
       
       
 
Figure 3.10c: Hisopathological examinations (20x) of the cardiac (heart) tissues of different 
animal groups at the end of the experimental period. NC: Normal Control; DBC: Diabetic 





 3.13.4 Kidney tissues 
The slides for histopathological examination of the kidney tissues are presented in Figure 3.10d. 
The slides revealed severe vacuolation and degeneration of the glomeruli, as indicated by the 
protrusion of the abnormally appearing glomeruli from the Bowman’s capsule, in the DBC, 
CAF20 and CAF40 groups while the NC group had a normal and perfectly intact glomeruli. 
Overall the glomeruli and mesangial cells of the CAF20 group had a physiologically healthier 
appearance compared to the CAF40 group but was worsened in the DBC group (Fig. 3.10d).  
 
           
           
Figure 3.10d: Hisopathological examinations (20x) of the kidney tissues of different animal 
groups at the end of the experimental period. NC: Normal Control; DBC: Diabetic Control; 






DISCUSSION AND CONCLUSION 
The main objective of this study was to develop an alternative non-obese non-genetic rat model 
for T2D that could closely resemble the major clinical pathogenesis seen in humans such as less 
insulin resistance with partial pancreatic beta-cell dysfunction which results in disorderly 
reduced insulin secretion (Vaag and Lund, 2007). Streptozotocin is usually used as a potential 
inducer of diabetes by selectively damaging the pancreatic beta-cells by increasing the levels of 
harmful ROS and in two previous studies (Masiello et al., 1998; Nakamura et al., 2006), 
nicotinamide pre-injection has been used as a technique to partially prevent the streptozotocin-
induced damage of pancreatic beta-cells in order to develop the non-obese animal models of 
T2D. On the other hand, after a short-term study, Kagami et al. reported that caffeine (100 mg/kg 
BW) pre-injection can successfully prevent the STZ-induced (65 mg/kg BW) pancreatic beta-cell 
damage in male Wistar rats (Kagami et al., 2008). Using this approach, different dosages (5-40 
mg/kg BW) of caffeine was pre-injected with a single dose of STZ (65 mg/kg BW) to induce an 
alternative non-obese non-genetic rat model of T2D. The results of this study suggest that 
caffeine pretreatment at 20 mg/kg BW in combination with a single injection (i.p.) of STZ (65 
mg/kg BW) can be an alternative and efficient way to develop an alternative non-obese non-
genetic rat model of T2D. 
 
Polydipsia, polyphagia, blurred vision and weight loss are some of the most common symptoms 
of diabetes (American Diabetes Association, 2007) which have been noticed in all diabetic 
groups in this experiment. The significantly higher food and fluid intake but significantly lower 
BW gain in the DBC, CAF20 and CAF40 groups compared to the NC group observed in this 
experiment might be due to a high loss of energy taking place via urinary glucose excretion and 
also due to the severity of diabetic conditions (Wilson and Islam, 2012). However, relatively 
lower food and fluid intake but relatively higher body weight gain in the CAF20 and CAF40 
groups compared to DBC group (Fig. 3.1, 3.2) revealed the suitability and stability of CAF 
consuming group as a better model for non-obese T2D because body weight is normally not that 
increased in non-obese T2D (Yamamoto et al., 2008). The body weight gain observed in a 
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previously developed nicotinamide-STZ injected rat model (Masiello et al., 1998) was inversely 
proportional to the level of blood glucose. Additionally, the age of the animals at the beginning 
of diabetes induction was significantly higher compared to the rats used in this experiment (12 
versus 6 weeks) which might facilitate the better adaptation against STZ-induced body weight 
reduction. Although nicotinamide and caffeine both partially protect pancreatic beta-cells from 
the STZ-induced damage (Kagami et al., 2008; Masiello et al., 1998), the mode of actions might 
be different from each other and our data is supported by the previously published caffeine-STZ 
based (Kagami et al., 2008) and caffeine-based diabetic studies (Greenberg et al., 2006; Park et 
al., 2007; Whitehead and White, 2013).  
 
The two major pathogenesis of T2D are insulin resistance and partial pancreatic beta-cell 
dysfunction (DeFronzo, 1997). Due to the partial pancreatic beta-cell dysfunction, the insulin 
secretion is partly affected in the case of T2D compared to type 1 diabetes (T1D) hence, the level 
of blood glucose is also usually lower in type 2 compared to patients with T1D. At the same time 
the pathogenesis of non-obese T2D is slightly different from obese T2D at least in terms of 
insulin resistance and insulin secretory capacity of pancreatic beta-cells. Apart from some 
previous studies (Kim et al., 2007; Nakamura et al., 2006), a most recent study reported that the 
patients with non-obese T2D seem to have lower insulin secretory capacities with mild, but 
evident, insulin resistance (Urakami et al., 2013). The HOMA-β and HOMA-IR scores are used 
to determine the insulin secreting ability of pancreatic beta-cells and the degree of insulin 
resistance respectively. In this study the diabetes-induced groups had a significantly lower 
HOMA-β scores in comparison to the NC group (120 ± 18.98), however, the CAF20 had 
significantly higher scores (3.90 ± 0.72) compared to the DBC (1.03 ± 0.21) and CAF40 (2.77 ± 
0.45) groups (Table 3.5) thus providing further evidence that caffeine pretreatment at 20 mg/kg 
BW offers better protection against STZ-induced beta-cell damage. HOMA-IR scores revealed a 
higher degree of insulin resistance in the diabetes-induced groups when compared to the NC 
group. Additionally, the level of blood glucose is often lower in T2D compared to TID and 
fasting blood glucose has been used as a marker for the diagnosis of non-obese T2D in several 
previous studies (Daniele et al., 2010; Masiello et al., 1998). The results of significantly lower 
fasting blood glucose (Fig. 3.3), lower glucose intolerance (Fig. 3.4 and Table 3.1) but 
significantly higher insulin concentrations (Table 3.5) and better pancreatic beta-cell morphology 
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(Fig. 3.10a) in the CAF groups compared to the DBC group support the possibility of CAF 
consuming groups as a non-obese T2D model when the results of CAF20 group are more 
appropriate due to relatively lower impaired glucose tolerance and higher insulin secretion 
abilities compared to CAF40 groups (Fig. 3.4, Table 3.1 and Table 3.5). Moreover, the mean 
fasting blood glucose of CAF consuming groups were sustained around 400 mg/dl during the 
entire 13 weeks period of the experiment whereas an increasing tendency of fasting blood 
glucose was observed in the DBC group around 500-550 mg/dl which resembles mostly with 
T1D animal models (Fig. 3.3).           
 
In TID, the serum insulin level is usually very low due to the severe or complete destruction of 
pancreatic beta-cells which is found in only the STZ treated DBC group in this study. On the 
other hand, significantly higher serum insulin levels in CAF groups compared to the DBC group 
revealed that the pancreatic beta-cell destruction by STZ was partly prevented by the pre-
injection of caffeine when better prevention was observed in the CAF20 compared to the CAF40 
group which is further supported by relatively lower glucose intolerance (Fig. 3.4 and Table 3.1)  
and lower serum fructosamine level (Table 3.5) and better pancreatic tissue histopathology in 
CAF20 group compared to the CAF40 group (Fig. 3.10a).  
 
There were no notable differences in pancreatic islet size between the CAF groups, however, the 
CAF20 group had more beta-cells and was morphologically healthier in appearance as compared 
to CAF40 group while the DBC group revealed substantial damage that was not seen in the 
caffeine groups (Fig. 3.10a). Caffeine may have compromised the effects of STZ by an unknown 
mechanism, which resulted in a much better morphological appearance of the pancreatic islets in 
the CAF20 and CAF40 groups compared to DBC group. The smaller size as well as the lower 
number of beta-cells in the pancreatic islets of DBC group compared to the CAF groups 
confirms the partial prevention of STZ-induced pancreatic beta-cells by caffeine pre-treatment. 
At the same time, the better morphology of pancreatic beta-cells in CAF20 group compared to 
the CAF40 group revealed that CAF20 group can be a better model compared to the CAF40 




Although liver glycogen content and most serum lipids are usually increased in the case of high-
fat diet-fed or obesity associated animal models of T2D (Islam and Choi, 2007; Srinivasan et al., 
2005), the status of liver glycogen and lipid profiles are different both in non-obese type 2 
diabetic humans and animals models (Billingham et al., 1989; Moringa et al., 2008; Yamamoto 
et al., 2008). Morinaga et al. (2008) reported the reduced glycogen synthase activity as well as 
glycogen content in the confirmed diabetic state of Spontaneously Diabetic Torii (SDT) rats, an 
established genetic model of non-obese T2D. On the other hand, in a previous study, Billingham 
et al. (1989) reported the increased concentrations of non-esterified and esterified cholesterol, 
triglyceride, phospholipid in adult patients with non-obese T2D when no significant difference 
was observed for LDL-cholesterol which is completely supported by the lipid profile data of our 
study (Fig. 3.6). Additionally, Yamamoto et al. (2008) reported a significantly higher plasma 
triglyceride and lower visceral fat and liver weight in a genetically-induced non-obese mouse 
model of T2D. The comparatively lower relative liver weights and liver glycogen levels of CAF 
groups compared to the DBC group (Table 3.4) are supported by the results of above-mentioned 
genetically-induced non-obese models of T2D (Yamamoto et al., 2008; Moringa et al., 2008). 
Hence, the data of liver glycogen and serum lipid profile of this model not only resemble with 
the pathogenesis of previously developed animal models of non-obese T2D but also to the 
human pathogenesis of non-obese T2D.  
 
Apart from the above-mentioned parameters, in order to understand the possible damage in the 
different organs which are closely associated with the complications of diabetes e.g. kidney, 
heart and liver, the levels of different serum parameters have been analysed (Table 3.6) and the 
histopathological examinations (Fig. 3.10b, 3.10c and 3.10d) of the above organs were 
conducted. Shrestha et al. (2008) reported that a higher serum creatinine and urea levels are 
positively associated with the level of blood glucose in people with diabetes and it has been 
suggested that the estimation of serum creatinine and urea levels along with blood glucose levels 
is necessary to understand the level of renal dysfunctions diabetic nephropathy. High creatinine 
levels are also present when there is a loss in body mass as seen in patients with diabetes 
(Gerchman et al., 2009) and this correlated with the relatively higher creatinine levels and 
significant loss of BW in the diabetic animal groups compared to NC group (Fig. 3.2 and Table 
3.6). The higher serum ASAT and ALAT levels are also used as the indicators of different organ 
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damage as well as hepatic insulin resistance and T2D (Cho et al., 2007; Harris, 2005; Hudson et 
al., 2012; Judi et al., 2010). Additionally, elevated serum LDH and ALP levels are also 
considered as the indicators of liver damage (Evliyaoğlu et al., 2011) and in a recent study, it has 
been reported that high ALP levels can be used as an indicator for nephropathy (De Carvalho et 
al., 2011) and hepatobilliary disease (Fernandez and Kidney, 2007). The acute overexpression of 
LDH was found in disturbed insulin secretion as well as in abnormal mitochondrial metabolism 
(Ainscow et al., 2000), and the patients with severe diabetes tend to have a high plasma activity 
of LDH (Evliyaoğlu et al., 2011). On the other hand, the elevated serum CK-MB levels are 
usually associated with cardiac muscle damage as well as diabetic cardiomyopathy due to the 
high blood glucose as well as high lipid levels (Evliyaoğlu et al., 2011). In this study the 
relatively, but not significantly, increased serum creatinine levels and the significantly increased 
serum urea, ASAT, ALAT, LDH, ALP and CK-MB concentrations in the diabetes-induced 
groups compared to the NC group revealed the early signs of diabetic associated complications 
and this was further validated by the histopathological examinations. The liver, heart and kidney 
of the NC group revealed a morphologically normal and healthier appearance of the hepatocytes, 
myocardium and glomeruli respectively. In contrast, with regards to the diabetes-induced groups, 
elevated levels of lipid accumulation, vacuolization and degeneration of the hepatocytes occurred 
in the liver, the heart muscle tissues of the myocardium displayed signs of deterioration as 
indicated by an increase in myofibril loss and an increase in cytoplasmic vacuolization, while a 
severe degeneration of the glomeruli and vacuolations was observed for the kidney. However, 
the relatively lower concentrations of above mentioned parameters (except CK-MB) and the 
morphologically healthier appearance of the liver, heart and kidney in the CAF groups compared 
to the DBC group (Table 3.6) again provides further support that this is a better model for non-
obese T2D. However, further study is needed to induce proper diabetic complications in this 
model, therefore this existing model may not be used as an appropriate model for any diabetic 
complications.  
 
The severity of tissue damages occurring in the liver, heart, kidney and pancreatic tissues of the 
diabetes-induced groups were further monitored using the TBARS, GSH, catalase, SOD, GR and 
GPx assays. As explained above, STZ causes an increase in detrimental levels of ROS and free 
radicals, as seen in diabetic patients, and as a result this plays an insidious role in tissue damage 
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which is supported by several studies (Bergamini et al., 2004; Forbes et al., 2008; Evans et al., 
2003; Ceriello and Motz, 2003; Chitturi and Farrell, 2001). Non-enzymatic protein glycations, 
glucose oxidation and oxidative breakdown of glycated proteins all contributes towards the 
formation of abnormally high levels of free radicals that is implicated in oxidative stress and  
tissue damage (Maritim et al., 2003). ROS causes high levels of lipid peroxidation in diabetics 
which contributes towards oxidative stress and tissue damage (Kesavulu et al., 2000) in the liver 
(Jaeschke, 2000), heart (Giordano, 2005), kidney (Susztak et al., 2006) and pancreas (Robertson, 
2004). The hydroperoxides formed, as a consequence of lipid peroxidation, tend to react with 
transition metals in the body such as copper and iron to produce stable aldehydes namely 
malondialdehyde that plays a role in destroying cell membranes (Maritim et al., 2003). GSH is a 
non-enzymatic antioxidant that protects organ specific tissues against free radical attack and 
oxidative damage which is commonly associated with the pathogenesis of diabetes and diabetics 
tend to have very low concentrations of cellular GSH (Anthony et al., 2009) and a decrease in 
NADPH levels (Maritim et al., 2003). Sekhar et al. (2011) reported that patients with 
uncontrolled T2D and persistent hyperglycemia have decreased levels of GSH synthesis which 
leads to an increase in oxidative stress and detrimental damages to the tissues. Hence, an increase 
in lipid peroxidation and reduction of hepatic GSH are considered to be a major characteristic 
feature of diabetes (Mukherjee et al., 1994). The TBARS assay was used to determine the rate of 
lipid peroxidation by monitoring the concentration of malondialdehyde, a lipid peroxide 
derivative, in the tissues and serum (Kakkar et al., 1995). The diabetes-induced groups had a 
higher lipid peroxidation levels compared to the NC group which was an indication of increased 
production of ROS and oxidative stress, however, the CAF groups had relatively lower levels 
compared to the DBC group which again highlights the protective effects of caffeine against 
oxidative damage (Fig. 3.7). The GSH levels of the NC group was significantly higher for all the 
tissues and serum samples compared to the diabetes-induced groups while the CAF20 group had 
a relatively higher GSH concentration and the least amount of oxidative stress-induced damage 
in the pancreas compared to the DBC and CAF40 groups (Fig. 3.8) which can be validated by 
the histopathological results (Fig. 3.10a). The data obtained from the GSH assay correlates with 
studies that found a decrease in GSH concentrations in the kidney, liver, heart, pancreas and 




As seen with non-enzymatic antioxidants such as GSH, antioxidative enzymes namely catalase, 
SOD, GR and GPx also play a crucial role in eliminating the deleterious effects of ROS and free 
radicals towards tissue damages. The hydroxyl and superoxide radicals induce detrimental 
damages to various organs and are considered to be the major contributing factors that mediates 
oxidative stress (West, 2000). SOD plays a role in converting the superoxide free radicals to 
hydrogen peroxide which, in turn, is converted to water by the catalase enzyme (Anthony et al., 
2009). GPx also plays a role in converting hydrogen peroxide to water by using GSH as a donor 
of hydrogen during this chemical reaction. In turn, GR converts the resulting GSSG back to GSH 
using NADPH (Martitim et al., 2003). Several studies reported on the presence of high 
antioxidative enzymatic activities in the liver, heart, kidney, pancreas and serum during 
uncontrolled diabetes and can be an indicator of tissue damage (Wohaieb and Godin, 1987; 
Kakkar et al., 1995; Genet et al., 2002; Maritim et al., 2003; Bergamini et al., 2004). Data for the 
catalase and SOD assay revealed a significantly higher enzyme activity in all tissues and serum 
samples of the diabetic groups compared to the NC group which are an indication of tissue 
damage (Fig. 3.9a and 3.9b) and can be further validated by the histopathological results (Fig 
10a, 10b, 10c and 10d). The pancreatic beta-cells express very low levels of GPx, SOD and 
catalase enzymes thus making them more susceptible to oxidative stress-induced damages 
(Valko et al., 2007), however, in this study caffeine pretreatment significantly protected the beta-
cells from STZ-induced ROS toxicity as seen from the catalase (Fig. 3.9a), SOD (Fig. 3.9b) and 
histopathological studies (Fig. 3.10a). A mixed trend of data was obtained for the GR and GPx 
assays (Fig. 3.9c and 3.9d). In 1992, Blakytny and Harding reported that high levels of fructose, 
glucose and glucose 6-phosphate inactivates the GR enzyme by a process known as glycation or 
non-enzymatic glycosylation (Blakytny and Harding, 1992) and fructosamine is regarded as a 
suitable marker for determining the degree of protein glycation in diabetics (Maritim et al., 
2003). Data obtained for serum fructosamine revealed that the CAF20 group had a significantly 
and relatively lower fructosamine levels compared to the DBC and CAF40 groups respectively 
(Table 3.5). This correlates with the significantly higher GR activity in the serum of the CAF20 
group compared to the DBC and CAF40 groups (Fig. 3.9c). Non-enzymatic glycation can also 
cause negative modifications to the function and structure of antioxidative enzymes by 
inactivating their ability to detoxify and scavenge free radicals (Maritim et al., 2003) which can 
attribute towards the mixed trend of data obtained for the GPx assay (Fig. 3.9d). An over 
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production or detrimental levels of free radicals can inhibit and inactivate antioxidative enzymes 
which can lead to a decrease in antioxidant enzyme activities in certain tissues (Genet et al., 
2002) and this might have contributed towards the mixed trend of antioxidant enzyme activity 
data obtained in this study.  
 
Finally, in order to evaluate the efficacy of this model, the anti-diabetic drug response tests have 
been performed by using two different but widely used anti-diabetic drugs such as metformin 
(insulin sensitizer) and glibenclamide (insulin secretogouge) (Ito et al., 2010; Takeda et al., 
1991). A significant reduction of blood glycated haemoglobin (HbA1c) and fasting 
hyperglycemia was observed in patients with non-obese T2D after the oral administration of 
metformin (Ito et al., 2010) and glibenclamide (Takeda et al., 1991). In this study, the significant 
reduction of blood glucose levels after the treatment of metformin and glibenclamide in both 
CAF groups (Fig. 3.5a, 3.5b and Table 3.2 and 3.3) not only suggest the sensitivity of this model 
to commonly used anti-diabetic drugs but also suggest its efficacy in the routine pharmacological 
screening of new anti-diabetic drugs. However, better efficacy of both drugs has been observed 
in the CAF20 compared to CAF40 group during these 3 hour period of anti-diabetic drug 





Data from this study suggest that caffeine pretreatment at 20 mg/kg BW with 65 mg/kg BW STZ 
injected (i.p.) rats can be a new and alternative non-obese non-genetic chemically-induced model 
for T2D since it mimics the major pathogeneses of non-obese T2D namely partial pancreatic β-
cell dysfunction and damage as well as disproportionally reduced insulin secretion. A stable 
diabetic condition was achieved during the 13 weeks experimental period and can be therefore 
used for both chronic and acute research studies as well as pharmacological screening of new 
anti-diabetic drugs. This model is advantageous to researchers globally since its induction time is 
very short, cost effective, easy to maintain and develop, does not require any special dietary 
formulations and can be used in developing countries where resources and funding are limited. 
Additionally, it does not require any sophisticated laboratory or instruments to develop as 
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Further studies need to be done to validate this newly developed model in assessing the anti-
diabetic effects of various anti-diabetic materials and newly developed anti-diabetic drugs. In 
addition, the suitability of this model needs to be compared with other previously developed 
genetic and non-genetic models of non-obese T2D to determine whether it mimics similar of 
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